Autism spectrum disorder

Catherine Lord, Traolach Brugha, Tony Charman, James Cusack, Guillaume Dumas, Thomas Frazier, Emily J Jones, Rebecca Jones, Andrew Pickles, Matthew W. State, et al.

► To cite this version:

Catherine Lord, Traolach Brugha, Tony Charman, James Cusack, Guillaume Dumas, et al.. Autism spectrum disorder. Nature reviews Disease primers, 2020, 6 (1), pp.5. 10.1038/s41572-019-0138-4 . pasteur-02445082

HAL Id: pasteur-02445082

<https://hal-pasteur.archives-ouvertes.fr/pasteur-02445082>

Submitted on 19 Jan 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Autism spectrum disorder

Catherine Lord^{1*}, Traolach S. Brugha², Tony Charman³, James Cusack⁴, Guillaume Dumas⁵, Thomas Frazier⁶, Emily J. H. Jones⁷, Rebecca M. Jones^{8,9}, Andrew Pickles³, Matthew W. State¹⁰, Julie Lounds Taylor¹¹ and Jeremy Veenstra-VanderWeele¹²

1 Departments of Psychiatry and School of Education, University of California, Los Angeles, Los Angeles, CA, USA.

2 Department of Health Sciences, University of Leicester, Leicester, UK

3 Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.

4 Autistica, London, UK.

5 Institut Pasteur, UMR3571 CNRS, Université de Paris, Paris, France.

6 Autism Speaks, New York, NY, USA.

7 Centre for Brain & Cognitive Development, University of London, London, UK.

8 The Sackler Institute for Developmental Psychobiology, New York, NY, USA

9 The Center for Autism and the Developing Brain, White Plains, NY, USA.

10 Department of Psychiatry, Langley Porter Psychiatric Institute and Weill Institute for Neurosciences, University of California, San Francisco, CA, USA.

11 Department of Pediatrics and Vanderbilt Kennedy Center, Vanderbilt University Medical Center, Nashville, TN, USA.

12 Department of Psychiatry, Columbia University, New York, NY, USA.

e-mail:

CLord@mednet.ucla.edu

Abstract

Autism Spectrum Disorder (ASD) is a construct used to describe individuals with a specific combination of impairments in social communication and repetitive behaviours, highly restricted interests and/or sensory behaviours beginning early in life. The worldwide prevalence of autism is just under 1%, but estimates are higher in high-resource countries. Although gross brain pathology is not characteristic of autism, subtle anatomical and functional differences have been observed in postmortem, neuroimaging and electrophysiological studies. Initially it was hoped that accurate measurement of behavioural phenotypes would lead to specific genetic subtypes, but genetic findings have mainly applied to heterogeneous groups that are not specific to autism. Psychosocial interventions in children can improve specific behaviours, such as joint attention, language and social engagement that may affect further development and could reduce symptom severity. However, further research is necessary to identify the long-term needs and treatments and the mechanisms behind them that could result in improved independence and quality of life over time. Families are often the major source of support for people with AUTISM throughout much of life and need to be considered, along with the perspectives of autistic persons, in both research and practice.

[H1] Introduction

Autism spectrum disorder (ASD) is a common, highly heritable and heterogeneous neurodevelopmental disorder that has underlying cognitive features and commonly co-occurs with other conditions. The

behaviours, strengths and challenges of people with autism, have attracted the attention of scientists and clinicians for at least 500 years (Fig. 1). Autism is a heterogeneous disorder and, reflecting this heterogeneity, the term autism has been used in various ways to describe both a broader presentation, and then a specific diagnosis when it was considered to be one subgroup within the general diagnostic category of ‘pervasive developmental disorders’ (PDDs), a group of disorders that was introduced in Diagnostic and Statistical Manual of Mental Disorders, Third Edition (DSM III) in 1980 to convey the idea of a broader spectrum of social communication deficits. Owing to lack of clear borders between the PDDs and difficulties in reliably distinguishing them, the current diagnostic systems, the International Classification of Diseases 11th Revision (ICD-11) and the DSM-5 use the umbrella term ‘ASD’, and differentiate individuals using additional clinical specifiers and modifiers. In this paper, we use the term “autism” to refer to ASD in general, both for brevity and out of respect for the preferences of self-advocates.

Manifestations of autism include impairments in social communication and interaction, sensory anomalies, repetitive behaviours and varying levels of intellectual disability (Box 1). Together with these core symptoms, co-occurring psychiatric or neurological disorders are common in people with autism, of which, hyperactivity and attention disorders (such as attention-deficit/hyperactivity disorder (ADHD)), anxiety, depression and epilepsy are fairly prevalent. A diagnosis of autism is reached after obtaining a detailed developmental history, often from the parents, and observation of the individual interacting with parents or other individuals^{1,2}. Early intervention for children with autism is key owing to common difficulties in communication. The types of interventions used change throughout life and include parent-mediated interventions and/or therapist-delivered interventions in childhood, school-based strategies and techniques to promote independence in adulthood. Pharmacological therapies can be used to treat some of the associated symptoms of autism, such as irritability, and comorbidities, such as anxiety.

This Primer discusses the epidemiology and mechanisms of autism, together with the diagnosis and treatment of people with this condition. Three themes are addressed: mechanisms of causality and change over time, heterogeneity within and between individuals with autism, and outcomes across the lifespan.

[H1] Epidemiology

[H2] Prevalence

Epidemiological administrative and community-based studies have suggested that autism is more common in males than in females, with reported ratios ranging from 2.1–5.1, with an estimate of 4.1 in the 2010 Global Burden of Disease study^{3,4}. The sex ratio is slightly lower in studies that use population-wide testing to find community cases within a population compared with the more common passive case-finding studies that review administrative data (for example, medical or special educational records), and that may result in less plausible associations and, therefore, artificially increase prevalence estimates⁵. Active case-finding that does not rely on administrative records has demonstrated an equivalent community rate of autism in men and women with moderate to profound intellectual disability⁴. Thus, even the most widely accepted tenet of our understanding of factors associated with autism is far from straightforward.

Estimates of the prevalence of autism in various populations and settings differ according to the method of ascertainment used in the study, including definition, sampling and the extent of independent population case assessment in contrast to administratively based sources. Of note, the Global Burden of Disease study uses all known data from administrative and community survey sources on a disease or disorder to model associations (particularly with time) to examine trends. In the 2010 GBD study, an estimated 52 million people had autism globally, equating to a prevalence of 1 in 132 individuals⁶. Worldwide, little interpretable variation in the prevalence of autism between regions, ethnicities or services and resource provision has been reported. Indeed, one systematic review did not find a strong effect of ethnic, cultural or socioeconomic factors on the prevalence of autism⁷. However, statistical power to detect any effects was limited in the available data sets, particularly in low-income countries. An increased prevalence of autism has been reported in migrant groups in some studies⁸ with few clear factors that might contribute to a greater prevalence in an Afro-Caribbean population in higher income countries^{9,10,11} in the absence of any evidence of geographical variation⁷. However, a survey of adults in the general population has shown that rates of autism in black and minority ethnic groups may be lower than in the rest of the population¹²; data from indigenous and Aboriginal cultures are very limited.

Many individuals and groups presume that autism rates are increasing over time, but this supposition is based on data from administrative records rather community-based studies. Indeed, after accounting for methodological variations between studies, there was no clear evidence of a change in the prevalence of autism in the community between 1990 and 2010¹³. In addition, general population and systematic case-finding community-based surveys (including testing of representative populations) have also confirm the lack of significant change in prevalence rates in childhood¹⁴ and adulthood¹⁵ over time. No significant evidence is available supporting that autism is rarer in older people, which provides further evidence against the suggestion that autism is increasing in prevalence over time⁴. Even in high-income countries with strong autism public health policies, there is evidence that autism in adults goes largely unrecognized, whereas administratively recorded diagnoses in children increase year by year¹⁶. This finding highlights the importance of obtaining information on autism rates in settings where professionals may be able to improve its recognition. The prevalence of autism in mental health inpatient settings is estimated to be far higher than in the general population, ranging from 4–9.9%¹⁷.

[H2] Environmental factors

One review of systematic reviews and meta-analyses of environmental risk factors for autism included a comprehensive coverage of the literature, a discussion of the limitations of research and the need for long-term prospective cohort-based studies to begin to address these limitations¹⁸ (Fig. 2). This and other studies identified environmental risk factors for autism as advanced parental age¹⁹ and birth trauma, particularly if due to proxies of hypoxia¹⁸. Moreover, maternal obesity, a short interval between pregnancies, gestational diabetes mellitus and valproate use during pregnancy have all been associated with increased risk of autism (Fig. 2). However, it should be noted that these factors cannot be considered causal, but could be reactive, independent or contributory for autism. Studies evaluating risk factors for autism that have reported an absence of association are equally, if not more important, to note, including clear evidence that autism is not associated with vaccination²⁰. Other negative associations include prolonged labour, delivery by caesarian section or assisted vaginal delivery, premature rupture of membranes and the use of assisted reproductive technologies, among other

factors (Fig. 2). Environmental risk factors could underlie risk of autism through several complex underlying mechanisms, such as genetic and epigenetic related effects (see Mechanisms/pathophysiology, below), inflammation and oxidative stress, hypoxic and ischemic damage¹⁸.

[H1] Mechanisms/pathophysiology

Many cognitive theories have been suggested to underlie the behavioural and developmental manifestations of autism, although the prominence and the consensus on the potential explanatory value of these theories have declined in the past decade. These theories range from 'social first' theories, such as the theory of mind (or mentalizing) and social motivational deficit theories, to global processing deficit theories including attentional control, executive dysfunction and weak central coherence or enhanced perceptual processing theories^{21,22}. Although many of these theories had a useful descriptive role and provide potential insights into differences in how autistic individuals might process and experience the world around them, the theories pertain to neurodevelopmental disorders in general and lack specificity for autism), largely non-developmental, applying only to a single point in time, and lack evidence as explanatory models. Nevertheless, they have been useful in clinical practice and underlie some recently proposed interventions, such as CBT-oriented treatments for anxiety²³.

Following cohorts of infants from gestation or birth to 2 or 3 years of age (that is, when a diagnosis of autism can be established) enables the study of the brain and behavioural manifestations of autism as they emerge²⁴. Indeed, prospective studies of infants with a relative with autism have yielded a number of insights into the mechanisms of this disorder. For example, infants who develop autism later in childhood have substantially typical profiles of interest in faces²⁵ and eyes²⁶ at 6 months of age, which have cast doubt on social orienting theories in which autism originates from a primary deficit in innate patterns of subcortically-mediated social orienting²⁷. In addition, subtle but diffuse differences in encephalography (EEG) and in other measures of brain function have been demonstrated in autistic people (see 'Findings from electrophysiological studies', below), which could represent alternative pathways to a common end-state phenotype or to whole-brain alterations in synaptic signalling pathways that have effects on development²⁸. Such considerations highlight the limitations of deterministic models of autism, in which a genetic change leads to a synaptic change that relates to a canonical symptom²⁹. Rather, there is likely a complex set of developmental interactions, in which the child's emerging brain activity and behaviour have bidirectional relationships to synaptic signalling and gene expression³⁰.

[H2] Genetics

Twin and family studies consistently demonstrate that autism has a particularly large genetic contribution, with estimated heritability ranging from ~40 to 90%^{31,32}. In addition, one analyses demonstrated that autism is among the most heritable common medical conditions³³. More than 100 genes and genomic regions have now been confidently associated with autism^{34,35}, mostly based on the study of heterozygous, germ-line, *de novo* mutations. These genetic changes range in size from a single

base (or nucleotide)^{36–38} to submicroscopic segments of DNA of thousands to millions of bases (also known as copy number variations (CNVs))^{39,40}. Whether these genetic changes lead to alterations in the sequence of DNA or the structure of the chromosome, changes that have a functional effect on protein-coding regions of the genome have the strongest and most reliable association with autism risk. Collectively, these *de novo* heterozygous mutations are rare and confer relatively large risks of autism⁴¹. With genetic studies now including cohorts of up to tens of thousands of individuals and the associated increase in statistical power, common, transmitted alleles of modest effect size, mostly corresponding to the non-coding regions of the genome, have begun to be identified⁴².

Studies of the genetics of autism contrast broadly with studies of adult-onset psychiatric disorders, in which most successful gene discovery has emerged from genome-wide association studies (GWAS), which assess common alleles of small effect size. Indeed, the earliest successes in autism presaged a more general finding that the contribution of rare, *de novo* mutations in coding regions of the genome is relatively greater among a range of early-onset disorders^{43–45} than for typically later-onset common conditions such as schizophrenia and bipolar disorder, although there is also a surprising degree of overlap in genetic risk for overtly disparate neuropsychiatric phenotypes that remains to be further elucidated³¹.

The extent to which rare, high effect size mutations account for autism risk raises some important definitional issues. Considering the overall population, the contribution of *de novo* mutations to autism risk is quite small (~3%)³². Indeed, the vast majority of individuals who harbour genetic risk for a common condition, particularly those with variants of small effect size, will never develop symptoms or need clinical attention. By contrast, there is a marked enrichment of individuals with rare and *de novo* mutations in the clinical autism population. Conservative estimates are that 10–20% of people with autism harbour a *de novo* rare point mutation or CNV contributing to their presentation^{34,46,47}. If the clinical population is constrained to those with autism who have a combination of factors including being female, having intellectual disability, multiple unaffected siblings or seizures, ~20–30% have a rare *de novo* mutation; if an individual has several of these risk factors, the yield of *de novo* sequence and structural mutations would be expected to be even higher³⁴.

However, irrespective of the precise proportion of risk conveyed by these mutations, their most substantial contribution to the understanding of autism is likely to be in elaborating the mechanisms of this disorder^{48,49}. In autism, a single *de novo* germ-line heterozygous loss-of-function point mutation can convey more risk than the cumulative effect of the top decile of polygenic risk for schizophrenia^{47,50}. Unfortunately, although manifestly more tractable than modelling hundreds of alleles simultaneously, addressing a single autism mutation at a time is not synonymous with an easy avenue to clinical care of most people with autism.

[H3] Molecular pathophysiology. Over the past decade there have been many studies using model systems to recapitulate so-called single gene (or monogenic) versions of autism, such as fragile X syndrome and tuberous sclerosis complex – which cumulatively are estimated to account for <10% of clinical cases of autism⁵¹. In addition, more recent studies have modelled the effects of rare and *de novo* mutations identified in idiopathic autism. This literature is far too vast to review comprehensively here^{52,53}. Although the study of autism risk genes in model systems has revealed a great deal about general biology, how these findings relate to the pathophysiology of autism is less clear^{48,49}. In general, autism risk genes tend to have a role in multiple functions in many brain regions that unfold in a

spatiotemporally defined manner across development. Consequently, although manipulation of a single risk gene in a model system may lead to interesting phenotypes—including social-behavioural phenotypes in evolutionarily distant organisms— it does not necessarily illuminate its contribution to human social disability. Moreover, although a single mutation can confer a several fold increase in the risk of autism, these variants do not demonstrate the type of causal clarity that is associated with classic monogenic neurodevelopmental disorders, such as fragile X syndrome, Angelman syndrome, Rett syndrome or tuberous sclerosis complex. In addition, the well-established sexual dimorphism of social disability adds yet another dimension to the expansive search space that exists between risk gene and human behaviour⁴⁸. The challenges of disentangling the spatiotemporal dynamics of risk gene expression and protein function are made even more difficult by the reality that these may play out differently in males versus females.

Owing to these challenges, multiple approaches have emerged focusing on convergence^{38,40,54–57}, that is, searching for points of commonality across different autism risk genes, with the reasoning that this approach could identify shared pathological mechanisms. In fact, the earliest successes in gene discovery quickly revealed important general properties that have held up well over time, including that, *prima facie*, most proteins encoded by autism risk genes are involved either in synaptic structure and function or chromatin modification and regulation of gene expression^{38,46,47,58} (Fig. 3). More recently, there has been an additional focus on spatiotemporal convergence and several studies have supported a nexus in mid-fetal, glutamatergic neurons during cortical development, with modestly divergent findings regarding deep⁵⁶ versus superficial⁵⁴ cortical layers. With improvements in technology, additional regions, including striatum, have also begun to emerge as points of potential risk convergence for autism⁵⁹.

The ability to constrain future experiments to examine mutations in specific risk-associated regional, cellular and developmental contexts should allow the narrowing in on relevant mechanisms. Of note, one study used single cell technologies to examine specific cell types and developmental stages using brain tissue from people with autism⁶⁰, and demonstrated changes in transcription in multiple cell types including upper-layer cortical neurons. These types of post-mortem studies ask important but somewhat broader questions from the approaches described above, such as underlying pathology and how the brain changes and responds to pathology over time. In these studies, similar to any cross-sectional study, it can be challenging to differentiate cause from effect. Consequently, the pursuit and intersection of studies that seek to define convergence early in development and those that examine subsequent molecular, cellular and circuit level changes will be critical to illuminating pathological mechanisms.

Indeed, given the success and FDA approval of gene therapy for early onset neurological disorders, particularly spinal muscular atrophy (SMA) type 1^{61,62}, targeting single genes of large effect in both idiopathic and monogenic autism is being viewed as increasingly plausible. As rare syndromes such as fragile X syndrome, Angelman syndrome and Rett syndrome have offered some of the earliest insights into autism biology, these disorders are also likely to lead the way in illuminating the practical and important ethical challenges that will attend such efforts for idiopathic autism. Efforts aimed at the highest confidence risk genes identified in idiopathic autism, such as *SCN2A* and *CHD8*^{34,35}, are almost certain to soon follow on attempts at gene therapy for monogenic neurodevelopmental disorders, in light of the growing list of well-defined large-effect targets, the increasing options for addressing haploinsufficiency⁶³, the ability to manipulate gene products without leaving a DNA “scar”^{63,64} and the

increasing ability to readily detect mutations—and intervene—in utero and very early in post-natal development.

[H2] Neurobiology

[H3] Findings from MRI Studies. MRI can facilitate understanding how the brain structurally and functionally develops differently in people with autism, although to date, MRI results in autism are not definitive. Although neuroimaging is typically more expensive than EEG and studies are limited by issues of replication, sometimes that is related to head motion that occurred during the scan which can erode signal⁶⁵, structural studies including those using diffusion tensor imaging (DTI)⁶⁶ and functional MRI (fMRI)⁶⁷ have accelerated our understanding of how altered neural circuits relate to clinical symptoms of autism^{68,69}. Studying circuitry in childhood that is specifically associated with the social brain (a network of brain areas involved with processing social information), including visual areas, areas of the prefrontal cortex, subcortex and areas integrating information (such as temporal parietal function and superior temporal sulcus), could also offer insight into the neural mechanisms of autism⁷⁰. In addition, MRI may facilitate understanding the heterogeneity of autism demonstrating subgroups of individuals with specific neurobiological alterations that could account for their symptomology. The summary of MRI studies in this section focuses on 0-2 years of age addressing biomarkers for autism. Prospective study designs are largely covered as they represent a significant portion of MRI research in autism.

The first MRI studies of autism focused on cerebral and cerebellar grey matter and white matter volumes in young children^{71,72}, although these studies were limited by studying toddlers and children ≥ 18 months, missing the opportunity to detect biomarkers of autism in the first year of life. More recently, longitudinal studies have obtained multiple brain MRIs of infants at high risk of developing autism (that is, those with a sibling with autism; known as baby sibling studies) during their first 2 years of life, and assessed these children for autism at this age. In these studies, detectable differences in brain structure were observed at 6 months of age in the fractional anisotropy trajectories for 12 of 15 neural fibre tracts in the brain in children diagnosed with autism at 2 years of age compared to children not diagnosed⁷³. Furthermore, abnormal growth in the cortical surface between 6 and 12 months of age and greater brain volume between 12 and 24 months of age was seen in children who were later diagnosed with autism, compared with those not diagnosed with autism⁷⁴ (Fig. 4). In addition, white matter integrity in the genu pathway at 6 months of age predicted the presence of restricted and repetitive behaviours at 2 years of age⁷⁵ and computational work demonstrated that whole brain functional connectivity at 6 months of age predicted a diagnosis of autism at 2 years of age⁷⁶. Collectively, these studies suggest the presence of disrupted neural pathways before the emergence of behavioural symptoms in children with autism, and might provide clues about the underlying neural mechanisms of autism. Although data from MRI studies has revealed differences in neurobiology between young children diagnosed with autism and those without⁷⁷, given that replication has been particularly difficult in these studies, more work is required before MRI can be used as a reliable biomarker of autism⁷⁸.

Task-based fMRI studies investigate circuits that are responsible for core challenges in autism (such as language production and comprehension⁷⁹), and have demonstrated hyper-activation of the superior

temporal gyrus and inferior frontal gyrus and hypoactivation of the bilateral middle temporal gyrus⁷⁶. In addition, these studies have demonstrated challenges in processing emotions in faces and the “social brain”⁷⁸, and deficits in attention⁷⁹. Studies have also shown greater sensitivity to sensory information, showing increased connectivity between the anterior insula and sensorimotor areas, and the anterior insula and amygdala, together was associated with greater sensitivity to slightly aversive sounds and tactile information⁸⁰. Although this area of research has revealed similarities or differences in people with autism compared with comparison groups, it has been limited by averaging data across many individuals, which can mask heterogeneity and differences across age groups. In addition, the work has been limited by small sample sizes and problems with replication that is likely caused by the many challenges with MRI data collection in people with autism, such as differences in data processing, inter-subject variability and data quality⁸⁰. Longitudinal imaging⁸¹ as well as associating neuroimaging data with longitudinal behavioural outcomes⁸² can address some of these limitations characterizing differences within participants.

Resting state functional connectivity MRI studies that require participants to look at a blank screen with no task demands have been used to study intrinsic connections in the human brain. Large datasets, such as the Autism Brain Imaging Data Exchange (ABIDE⁸³), have enabled researchers to pool data to allow more highly powered studies to address known limitations of small sample sizes and many dataset have relied on resting state studies to study neural connectivity in autism. In these studies, evidence has emerged of both hyper-connectivity and hypo-connectivity in short-range and long-range connections throughout the brain^{84,85}. Differences in results between studies could be due to the age of the participants⁸⁶, sex differences, heterogeneity, methodological concerns⁸⁷ or that both connectivity states exist in autism.

In future, MRI could be well suited to categorize subgroups of autism⁸⁸, as well as parsing out commonalities and distinctions among other developmental disorders⁸⁹. Using MRI to better understand differences between boys and girls on the spectrum⁹⁰, such as differences in whole brain connectivity⁹⁰ or the social brain⁹¹, a field in its infancy, or as a marker of biological change due to treatment has growing interest⁹².

[H3] Findings from electrophysiological studies. EEG has been historically used for the diagnosis of comorbid epilepsy in people with autism⁹³ although it can also be used to study the mechanisms of autism. Compared with MRI, EEG is more economical, easier to use and less invasive—which is particularly important for paediatric populations—whilst granting access to brain dynamics at millisecond timescales. Magnetoencephalography (MEG), although more expensive, provides higher spatial resolution than EEG.

Since the early recordings, the first focus of quantitative EEG was to study people with autism in task-free conditions. Pioneering studies have revealed alterations in oscillatory activity during the resting state in people with autism, with more slow waves and less alpha waves, as well as less intra-hemispheric and inter-hemispheric asymmetry compared to people without autism⁹⁴. More recent work has demonstrated the presence of developmental trajectories as revealed through increasingly sophisticated spatio-spectral analyses, and has revealed how differences in the trajectories of EEG power in high-risk infants may represent an endophenotypes of autism^{95,96}.

In terms of mechanisms, other studies have started to focus on task-based modulation of cognitive function, such as low-level perceptual anomalies and action observation that relate to the autism phenotype. One theory proposing a specific failure in autism of the ability of the brain to ‘mirror’ observed actions of another person (thereby named the ‘broken mirror’ theory) was based on altered μ -wave suppression in autism⁹⁷ but was later questioned both theoretically^{98,99} and empirically^{100,101}, pointing toward a more complex picture of dysfunctional executive functions and visual attention¹⁰². Other studies, particularly those assessing event-related potentials (ERP), have demonstrated the modulation of sensory processing in people with autism, with observed changes in sensitivities and latency¹⁰³. Differences in auditory and visual processing could have a role in the development of core features of autism, such as language delay and difficulty in emotion recognition although this hypothesis requires further study. Although perceptual processes appear different in people with autism, the electrophysiological underpinning is still far from clear regarding the main ERPs like the MisMatch Negativity (MMN)¹⁰⁴ or the N170¹⁰⁵. Although data from meta-analyses have suggested smaller MMN amplitudes and delayed N170 latencies on average in people with autism compared to typically developing controls, additional studies are required that account for the large heterogeneity of this disorder, by moving away from averaging the data to focus either on specific subgroups¹⁰⁶ or refined modelling strategies that can capture individual differences in developmental trajectories⁹⁵. Although this avenue of research has not yet been fully explored, interactive tasks that encompass real-time social interaction could allow the study of brain activity in experimental contexts that are more relevant for core autism symptoms, rather than the more passive tasks that are used in most functional imaging studies¹⁰⁷. Experiments focusing on human-human interaction¹⁰⁸ and human-machine interaction¹⁰⁹ have been undertaken but, so far, no study has ever made explicit use of such methods to study the electrophysiology of autism.

In a further search for mechanisms of autism, prospective baby siblings studies have suggested that the gradual emergence of behavioural symptoms of autism is preceded by earlier subtle alterations in the activity of regions and networks of the social brain²⁴. For example, early work on a small group of 5–6-month-old infants who later developed autism observed faster but less prolonged neural activation and delayed sensitization responses to faces compared with infants who did not develop autism¹¹⁰, and one report demonstrated that newborns with an increased familial likelihood of autism showed higher signal homogeneity within core social brain networks (right fusiform and left parietal cortex¹¹¹). By comparison, reduced frontal power, particularly in the high-alpha band, during quiet play at 3 months of age¹¹² and cortical hyperexcitability in the right tempo-parietal region during auditory repetition of pure tones at 9–10 months of age have been found in babies at familial risk for autism¹¹³, suggesting that atypical patterns occur in brain regions other than those involved in social processing. Such alterations could have a cascading effect on social learning and contribute to the later emergence of behavioural symptoms of autism, although a causal link remains to be demonstrated. Replications across different research centres are needed because many of these studies had small sample sizes, different definitions of groups and varied measures and time points.

Interestingly, results from MEG and EEG studies jointly point toward two physiological mechanisms of autism: excitation/inhibition (E/I) imbalance and alteration of large-scale functional interactions of brain systems as quantified through connectivity analysis¹¹⁴. An E/I imbalance is supported by results from computational modelling of how reductions in the amount of inhibition can account for the previously observed perceptual consequences of autism¹¹⁵ and transcranial magnetic stimulation (TMS) studies

demonstrating a neurophysiological deficit in γ -aminobutyric acid (GABA) receptor-mediated function in people with autism¹¹⁶. In parallel, decreased long-range functional connectivity has also crystalized as a consistent mechanism¹¹⁷. MEG studies have especially suggested a complex functional connectivity pattern in the somatosensory cortex with reductions in the feedback (top-down) direction, but increased in the feed-forward (bottom-up) direction¹¹⁸. Clarifying the extent to which this pattern is a methodological artifact that could result from the predominant average-brain approach, as suggested by fMRI studies, is critical¹¹⁹.

Beyond use to understand the pathophysiology of autism, the scalability and accessibility of EEG suggest that this technique could be an ideal candidate for use as a brain-based biomarker. Measures from information theory have already provided promising case-control classification¹²⁰, but developing generalizable biomarkers may require a combination of multiple EEG measures supported by robust machine learning methods¹²¹. Against the background of the current reproducibility crisis that characterizes many studies¹²², as well as the defining heterogeneity of autism, the next breakthrough will certainly demand large-scale collaboration between researchers and clinicians.

[H1] Diagnosis, screening and prevention

Diagnosis of autism is made on the basis of behavioural presentation. Although substantial heterogeneity exists between and within individuals across development, a set of core diagnostic features of autism (covering social interaction, communication and flexible or sensory behaviour) can be reliably identified by trained clinicians^{123,124}.

[H2] Diagnostic criteria

The re-formulation of the diagnostic criteria for ASD in the DSM-5 (Box 1)¹²⁵, which is similar to the criteria in ICD-11¹²⁶, contains several changes from previous editions that were based on good empirical and clinical evidence¹²⁷. First, the sub-classification of 'Asperger's disorder' was subsumed under the unitary term ASD as the diagnosis was inconsistently applied even by expert groups¹²⁸. This change is controversial, but the evidence supporting the inclusion of Asperger's disorder as a separate condition is very weak¹²⁹. The important questions are how better to consider the factors that characterize differences among autistic individuals and ensuring that these differences are measured and addressed using neurobiological and clinical research, rather than contained within very poorly defined categories of Asperger's and PDD Not Otherwise Specified (NOS) as defined in DSM-IV¹³⁰. In addition, some individuals with social communication problems but not restricted and repetitive behaviours who would previously have fallen into the now-removed subcategory of PDD-NOS now receive a different diagnosis of Social communication disorder, which is not yet well-validated. Although these changes have led to concerns that the DSM-5 ASD criteria are more restrictive than those in DSM-IV, many clinicians feel that the changes better reflect clinical consensus and practice. Second, the social and communication domains of the diagnostic criteria were unified to reflect the factor structure of symptomatology. Third, sensory anomalies (hypersensory and hyposensory responsiveness and sensation-seeking) in DSM-5 were included under the 'restricted, repetitive behaviours and interests' domain to reflect their pervasiveness¹³¹. Fourth, the DSM-IV criteria required symptoms to be present in the first 3 years of life,

but criteria in DSM-5 recognise symptom onset occurring in the early developmental period with the caveat that symptoms might not fully manifest until social demands exceed limited capacities. This change recognizes the developmental nature of autism, wherein for some individuals, clear manifestation of autism might not be apparent until mid-childhood, adolescence or even adulthood. In addition, late diagnosis (that is, diagnosis beyond early childhood) can occur even in those who received intensive early monitoring¹³². In addition, the DSM-5 criteria supports the use of specifiers that can denote those with a dual diagnoses, such as individuals with ASD and ADHD or other psychiatric disorders, as well genetic conditions such as fragile X syndrome or down syndrome. Beyond the clinic, these changes have implications for large-scale data pooling efforts; for considering domains of behaviour to be modelled; and for identifying shared and distinct developmental pathways to conditions like autism and ADHD.

[H2] Diagnosis and screening in children

The two core elements of the diagnostic process of autism in children are a detailed developmental history that is usually obtained from parents, covering first concerns and early history to the present day, and an observation of the child's interactions with their parents and with unfamiliar adults during a combination of structured and unstructured assessments. Ideally, observations of the young person in peer-group settings such as school or nursery would also form part of the diagnostic process. Of note, in one population-based study in the UK, girls with similar levels of symptom expression to boys were less likely to receive a diagnosis of autism from clinical services¹³³. This finding might reflect socio-cultural factors in the application of the diagnostic criteria, greater resilience or protective factors in girls that reduce the need for clinical services at a given symptom level, or the need for the revision of instruments used to identify symptoms to more fully cover female autistic traits¹²⁷

A number of structured diagnostic interviews and observational assessments for autism exist, but only a limited number have been rigorously tested for diagnostic accuracy relative to the gold-standard of expert clinician judgement. Although these interviews and assessments have reasonably robust sensitivity, specificity and reliability (see¹³⁴ for a review) and are widely used in some services in communities¹³⁵, there are also challenges to the widespread adoption of the best validated instruments: the Autism Diagnostic Interview–Revised (ADI-R¹³⁶) and the Autism Diagnostic Observation Schedule–2nd Edition (ADOS-2¹²³). These challenges include the cost of the instruments and training, the time required to complete them and the need for substantial training to use them reliably¹³⁷. Although expert clinical judgement was previously believed to be more reliable than reliance on instrument scores alone for the diagnosis of autism¹³⁸, more recent evidence suggests this may not be true at least in toddlers and preschool children¹³⁹. The need to take a global perspective on autism is driving attempts to develop more scalable tools, but this work is currently in its infancy (Box 2)¹⁴⁰.

The stability of a diagnosis of autism from the preschool years to mid-childhood is relatively high¹. However, although diagnostic systems currently presuppose that autism is a lifelong condition, there is a growing recognition that autism has a heterogeneous developmental time course¹⁴¹. Indeed, sub-groups of individuals with autism and improving or worsening symptoms over time can be identified^{142,143}. Such developmental trajectories might be a more meaningful phenotype on which to map aetiological mechanisms than a static case-control dichotomy^{74,144,145}. Some individuals diagnosed as children have

no clinically meaningful (or even detectable) impairment later in life (so-called ‘optimal outcome’^{146,147}); one critical question in identifying mechanisms is whether this profile is associated with successful effects of early intervention or is an aetiologically distinct subtype of autism.

[H3] Screening and early identification. The potential for early testing to prospectively identify children with autism at a young age has considerable interest, and several studies have evaluated the performance of parent-report instruments between 14 and 24 months of age, such as the Modified Checklist for Autism in Toddlers (M-CHAT) and the Early Screening of Autistic Traits (ESAT)^{134,148,149}. However, there are contrasting views on the strength of the evidence for universal population-wide testing, also known colloquially as screening^{150,151}. Of note, research is lacking on the effectiveness of therapeutic interventions in those identified with autism through universal screening. In addition, although it is possible to identify some children with autism before parents or professionals have identified concerns, diagnosis is missed in many children¹⁵², and most tested cohorts have not been systematically followed up to identify later-onset autism in children who initially tested negatively¹⁵³. Screening also often identifies children with broader developmental difficulties as well as those with autism¹⁵⁴. In general, such instruments could be more useful for identifying possible signs and symptoms of autism in high-risk populations, for example in young children with older siblings with autism¹⁵⁵, or in those referred for speech or other developmental concerns to community paediatric services¹⁵⁶. In addition, population-wide testing may also play a part in improving awareness and recognition of the early signs and symptoms of autism in both professionals and the general public, which alongside ongoing developmental surveillance pathways in community services, could help to bring down the age of recognition and diagnosis. These principles also apply in low-income and middle-income countries in which testing for autism and other neurodevelopmental disabilities has only just begun to be developed¹⁵⁴. Very little research has been devoted to cultural and ethnic differences in either child early presentation and parents’ understanding or the experience of autism, which may in fact affect how screening instruments work and thus impact on parents and families as much as autistic individuals.

[H3] Early developmental profiles. Understanding of onset patterns of autism has dramatically expanded over the past 10 years, through work on infants with a first degree relative with autism, who due to the high heritability of the condition have a 20% chance of developing autism themselves²⁵. Symptoms of autism have a gradual developmental onset. Indeed, although the average age of autism diagnosis remains ~4–5 years of age¹⁵⁷, parents typically report first concerns to health professionals at ~2 years of age¹⁵⁸. In many individuals, symptoms emerge during the second and third year of life (although, as per the DSM-5 onset criteria above, in others, onset might not be noticed until the child reaches school-age or later) whereas in others, symptoms become apparent after a seeming period of typical development, including a period of regression or stasis. To this end, conceptualization of what has been called ‘regression’ prior to 2 years of age has been reconsidered^{159,160}. Over the first two years of life, a substantial proportion of infants who later receive autism diagnoses show gradually accumulating delays across social, communication and language domains, suggesting that ‘regression’ represents a spectrum ranging from frank loss of acquired skills, to a gradual erosion (or ‘plateauing’) of developmental potential to individuals in whom these skills never emerge¹⁶¹.

[H2] Diagnosis and screening in adults

Information on diagnostic methods to identify autism in adulthood is in its infancy, with little methodologically acceptable evaluation of interview methods or screening questionnaires (including self-completion questionnaires). Clinical approaches rely heavily on extending methods developed for use in childhood to adulthood. These methods tend to rely on childhood developmental data, although validation research in adult general population-wide testing suggests good specificity and sensitivity for the observationally based ADOS Module 4 (Ref. ¹⁶²). However, typically, much research has depended on the judgment of expert clinicians and of standardized data collection on early child development that is unlikely to be obtainable for many older adults. Given that (undiagnosed) autistic adults presenting for an autism assessment are also more likely to have co-occurring adult mental health disorders, any method of assessment must be capable of differentiating such abnormalities in symptoms and behaviour from abnormalities due to autism. This point has led to the suggestion that clinical examination methods to identify adult psychopathology could be extended to include autism in addition to depression, anxiety and psychosis, among other disorders¹⁶³. Semi-structured adult psychopathology interviewing has been fruitful in the assessment of closely related neurodevelopmental disorders in adults, most notably ADHD¹⁶⁴. Given that most people in the world who are autistic are adults, and as many of these individuals have not received a diagnosis of autism^{4,15}, the development and evaluation of such adult assessment approaches is an urgent research priority.

[H2] Co-occurring disorders

In addition to the core features of autism, co-occurring difficulties or disorders (Fig. 5) are much more widely recognized in research^{165,166}, although they are not necessarily adequately addressed in clinical practice¹⁶⁷. For preschool children with autism, language delays, motor problems, epilepsy, difficulties with sleep and eating, and high levels of activity are most commonly observed^{168,169}. By comparison, ADHD, anxiety, obsessive-compulsive disorder (OCD), intellectual disability, academic challenges, irritability and disruptive behaviours become more apparent in school-aged children¹⁷⁰. The proportion of individuals with depressive symptoms becomes higher in adolescents and adults¹⁷¹, whereas other issues often remain. Moreover, growing evidence (although it is reliant on administrative case-finding data) suggests that people with autism have premature mortality^{172,173} and increased risk of self-harm and possibly suicide, although the mechanisms involved have yet to be elucidated. Studies using electronic health records have demonstrated that adults with autism are more likely to be diagnosed with many physical health conditions such as immune conditions, sleep disorders and obesity, compared with adults in the general population¹⁶⁷.

Collectively, these difficulties and disorders contribute to autism severity¹⁷⁴ and independence and well-being at each age¹⁷⁵. However, it is important to note, in the context of heterogeneity, that the prevalence of each of these co-occurring conditions varies considerably with the context of the sample (such as from psychiatry referrals, neurological referrals, or schools) and the methodology used (administrative, self-report or assessed), as well as with age, level of cognitive function and perhaps region¹⁶⁶). As many of these conditions are treatable, they are very important as clinical considerations but are also more complex than sometimes conveyed.

537 [H1] Management

538 [H2] Early intervention

539 Early intervention is seen as a priority because many young children with autism struggle to
 540 communicate and interact with others, restricting their opportunities to learn and affecting their
 541 parents who can find their child's behaviour perplexing and challenging to manage. Thus, outcomes of
 542 such interventions include changes in the individual's availability for learning and increased parent
 543 understanding. Intervention delivered in the preschool years at an age when there is increased brain
 544 plasticity might lead to additional benefit, although this theory has not yet been empirically supported.

545 The primary models of psychological intervention for preschool children with autism are developmental
 546 and behavioural. Although some consensus has been reached on the interventions that have more
 547 supporting evidence (termed 'naturalistic developmental behavioural interventions'¹⁷⁶), there is some
 548 uncertainty and disagreement about the strength of evidence for different approaches, with almost no
 549 direct comparisons of treatments or studies to assess which child should receive what treatment or
 550 treatment intensity. Indeed, clinical trials in autism are limited by cost, time, placebo effects and limited
 551 outcome measures, and are far behind much of the other research. This gap leaves parents and
 552 practitioners at the mercy of what is available and sometimes marketed in their region. Indeed, access to
 553 early intervention services is variable in most communities, including in high-income countries, and is
 554 mostly carried out by non-specialists supervised by specially trained professionals. In low-income and
 555 middle-income countries, most children and young people with autism — similar to those with
 556 intellectual and developmental disabilities — will not receive specialized services¹⁷⁷, although a number
 557 of groups have begun to test community delivery of early intervention in such settings¹⁷⁸.

558 Many current interventions build on the original 'Applied Behaviour Therapy'¹⁷⁹ (ABA) and have shifted
 559 to more natural, child-initiated developmentally appropriate strategies and tasks instead of dependence
 560 on repeated 'discrete trials' (known as discrete trial training, or DTT). In addition, considerable variation
 561 exists between different intervention models in terms of mode of delivery (for example, parent-
 562 mediated versus therapist-implemented), length (12-week versus 2-year programs), intensity (from a
 563 few hours a week to ~15 hours per week) and the balance between the developmental or dyadic versus
 564 behavioural components.

565 Lower-intensity approaches include parent-mediated interventions whereby parents are coached to
 566 become more attuned to their child's communication signals and style (which are considered an
 567 intermediate child outcome) and to facilitate more joint engagement in play and everyday activities,
 568 designed to increase social and communication skills in the child¹⁸⁰. Some studies have demonstrated
 569 enhanced joint engagement and joint attention (which are considered important intermediate child
 570 outcomes), with these lower-intensity approaches in preschool children compared to a control group,
 571 such as the 12-week Joint Attention Symbolic Play Engagement and Regulation (JASPER) program, both
 572 when delivered by parents in the home¹⁸¹ and by teaching assistants in school¹⁸². However, other lower-
 573 intensity, time-limited parent-mediated interventions such as Focus Playtime Intervention (FPI)¹⁸³ have
 574 not improved child outcomes (such as social orienting and joint attention), although some interventions
 575 have increased parental responsiveness¹⁸⁴. A longer program (Preschool Autism Communication Trial
 576 (PACT)), which consists of fortnightly parent-therapist sessions for 6 months, then monthly sessions for
 577 another 6 months, demonstrated improvements in parent and child dyadic behaviours such as parental
 578 synchrony and child initiations when interacting with each other (those close to the intervention target)
 579 but not symptom reduction at immediate follow-up¹⁸⁵. A subsequent 6-year follow-up to mid-childhood

at age 7 to 11 years identified modest reductions in overall autism symptoms using the ADOS over the whole course of the study that were not detectable at the immediate endpoint, suggesting that a longer-term perspective is critical in considering outcomes¹⁸⁶.

A higher intensity, more comprehensive approach is the Early Start Denver Model (ESDM), which combines behavioural and developmental or dyadic approaches. The ESDM is delivered by therapists for ~15 hours per week, and as part of this programme, parents are trained to improve social communication and interaction with their child. A small-scale trial demonstrated improvements in child developmental and adaptive outcomes, primarily in the language and communication domains, following 2 years of ESDM compared with treatment as usual¹⁸⁷. One larger multi-site trial found attenuated benefits with improvement in language outcomes at two of the three trial sites, but no differences between the treatment as usual and ESDM groups in overall developmental ability, adaptive behaviour or autism severity^{188,189}.

Many of these early intervention approaches are based on models of typical development. Increasingly, studies are using a combination of methods to define treatment outcomes and to better understand the mechanisms and models of change of interventions. These methods include analysis of the degree to which changes in the direct target of the intervention (for example, parent behaviour) mediate later changes in child behaviour¹⁸⁶, and the use of experimental methods such as EEG to examine whether there are accompanying changes in relevant brain networks¹⁹⁰. Many parents seek complementary medical approaches, which to date have not been supported and sometimes are dangerous¹⁹¹. A note of general caution is that even in the context of significant treatment differences between groups, individual outcomes are very variable, and some children do not improve, although reliable predictors of response to treatment have not been demonstrated in rigorous, randomized controlled trials. As autism is a heterogeneous developmental condition, different interventions may be required at different stages throughout life and different individuals might benefit from different interventions. One area which many consider to hold much promise, that of neurobiologically or biomarker 'informed' psychological intervention, is on the horizon but such targeted therapies have not yet been developed.

[H2] School age children and adolescents

Many children and young people with autism can also benefit from interventions at later ages. A number of programs and approaches are available that focus on the core social communication difficulties of autism; for example, social skills training programs for which moderate evidence of benefit exists^{192,193}. In addition, non-verbal young people with autism can benefit from use of augmentative communication systems, such as the Picture Exchange Communication System (PECS) and more sophisticated speech generating devices that use picture symbols and behavioural training methods to allow children to request and make choices¹⁹⁴ or other technology-based augmentative communication systems. Increasingly, more generic interventions that target co-occurring emotional and behavioural problems are being adapted for youths with autism, and initial studies suggest moderate benefits¹⁹⁵. These interventions include modified cognitive behavioural therapy (CBT) for anxiety (modified, for example, to include parents, increase the duration of sessions, use more visual materials and specific work on understanding one's own emotion states)¹⁹⁶ and parent-mediated interventions for disruptive behaviour and ADHD¹⁹⁷. More recently, there have been efforts to develop and test interventions that target aspects of parental wellbeing, such as parental stress and self-efficacy¹⁹⁸. Increasingly, interventions for school-age children and young people with autism are being delivered within the school environment, rather than the clinic, which has natural advantages for programmes that consist of

groups or peer-to-peer interactions and an emphasis on social skills. Indeed, it is hoped that this approach may facilitate generalization of the skills learned^{199,200}.

[H2] Adult services

As individuals with autism progress into and through adulthood, the focus of management shifts from treating the core symptoms of autism to addressing associated symptoms or behaviours and promoting independence. However, there are few intervention studies to guide treatment options in adulthood. Indeed, a 2012 systematic review identified only 32 studies published between 1980 and 2010 that evaluated treatment studies for adolescents and young adults with autism²⁰¹. A more recent review identified 41 studies of interventions targeting social functioning in adults over a 37-year period²⁰².

Despite the low number of treatment studies, there is some evidence supporting treatment efficacy for a limited number of symptoms, behaviors, and functional outcomes such as employment, social skills, and anxiety; however, in general, the evidence-base is weak^{201,202}. For example, only three randomized controlled trials (all of which included small cohort sizes) that tested job interviewing skills curricula have been published. Social skills interventions have a somewhat more robust literature base (see²⁰² for review), but most of these studies had very small sample sizes and were not well controlled. In addition, it is unclear whether social skills interventions can be generalized to other social settings and situations, that is, whether skills learned in the treatment context are used by the participants in other settings, such as with peers or at work. There is some evidence for the use of cognitive-behavioural therapy (CBT) for effectively treating anxiety in people with autism who have sufficient cognitive and language skills to participate in current programs²⁰³. However, nearly all of the existing research has been conducted with children and adolescents rather than in adults²⁰², and individuals with substantial communication challenges are excluded from CBT studies. Furthermore, in contrast to the general population, CBT has not yet been shown to be effective for the treatment of depression in individuals with autism. Given this weak evidence base, it may be fruitful to explore therapies and treatments tested in other groups that may benefit those with autism.

Formal service systems and social care can help fill in the treatment gaps. Indeed, although many adults with autism do not receive adequate services and support²⁰⁴, their receipt can improve outcomes across a number of domains¹⁶³. For example, transportation services can allow adults with autism to engage in employment and access therapies and programs in the community. In addition, comprehensive job support services can promote finding and maintaining employment, particularly for adults with more severe impairments²⁰⁵. Public health insurance can increase access to psychiatric care for those with co-occurring mental health problems, and income supports can reduce dependence on families.

[H2] Medications

All medications that have evidence of benefit for autism treat the associated symptoms or co-occurring diagnoses, rather than the symptoms of autism directly (including social communication or repetitive behaviours). As mentioned earlier, autism is an extremely heterogeneous disorder, and individuals with autism can have a number of common co-occurring disorders that can also vary in severity.

Risperidone and aripiprazole (both of which are often termed ‘atypical antipsychotics’) are approved in the USA to treat irritability and agitation — including aggression, self-injury and tantrums — in children and adolescents with autism^{206–208}. However, both treatments are associated with adverse events, including sedation, risk of movement disorders and weight gain, which limit their use to people with severe irritability with agitation²⁰⁸. The anti-diabetes drug metformin has been shown to limit weight gain from these medications, possibly broadening their safe use²⁰⁹.

As mentioned previously (see Co-occurring disorders, above), co-occurring mental health conditions are common in people with autism. Methylphenidate, atomoxetine and guanfacine are beneficial for ADHD symptoms in autism (Table 1 (Refs. ^{210–212})). Although serotonin reuptake inhibitors (SRIs), such as fluoxetine and citalopram, are used for the treatment of depression, anxiety and OCD in the general population, their efficacy in people with autism is less well established. Indeed, although fluoxetine improves symptoms of OCD in adults with autism²¹³, citalopram has demonstrated poor tolerability and no benefit for repetitive behaviour in children with autism²¹⁴. Medications for depression or anxiety have not been tested in people with autism.

Some excitement has accompanied the recent studies of medications targeting the neurohormonal oxytocin or vasopressin systems, both of which modulates social behaviour across species. Underpowered studies of intranasal oxytocin have demonstrated mixed results that are overall not supportive of a large effect size^{215,216}, with results pending from adequately powered studies (NCT01944046). In addition, a pilot study of intranasal vasopressin suggested possible benefit in people with autism, although this study was underpowered²¹⁷. A large trial of balovaptan, a vasopressin AVPR1A antagonist in adults with autism showed negative results on its primary outcome (a general rating of autism symptoms), with suggestive results on a key secondary parent report measure of adaptive behaviour, including social and communication behaviour²¹⁸. A few studies have also focused on the hypothesis that, at the level of neural circuits, autism may result from excessive excitation or insufficient inhibition²¹⁹, with some promising but inconclusive results for medicines that target the GABAergic system²²⁰. Medications targeting genetic syndromes that can cause autism have not yet yielded consistent improvement^{221,222}, but there is much hope for a precision medicine approach that links genetic subgroups with neurobiology-based treatments.

[H1] Quality of life

[H2] Objective and subjective measures

Several aspects of intervention research speak straight to the heart of current debates within the clinical field and broader autism community, including how a good outcome is defined for an individual with autism, as well as who should decide what outcomes are used in intervention studies²²³. This point is aligned both with the debates about medical versus social models of disability but also with a more general shift in medicine away from focusing on symptom reduction to improving the wellbeing and quality of life (QOL) of patients. QOL research in adults with autism has focused on two aspects: objective and subjective QOL. Objective QOL encompasses social achievements such as employment, adequate living conditions, supportive relationships, and good physical and mental health²²⁴, whereas subjective QOL focuses on individuals’ perceptions and subjective assessments of their own lives²²⁵.

Both subjective and objective QOL are often related, but not synonymous, and both are important to take into account when considering outcomes for individuals with autism (Table 2).

[H3] Objective QOL. Adults with autism tend to have poor objective QOL. Unemployment is high in this population, and even among those employed, individuals are often working below their skills and abilities^{226,227}. Moreover, independent living can be a challenge, and adults often lack meaningful relationships with peers²²⁸. When aggregating across these domains of life, many adults with autism have ‘poor’ or ‘very poor’ outcomes^{229,230}.

Autism is a highly heterogeneous condition and several factors have been associated with higher versus lower objective QOL. Most of the studied factors associated with higher objective QOL have been characteristics of the individuals (versus families, service system or communities), and consistent predictors of higher objective QOL include better early language development, higher IQ and adaptive behaviour scores, less severe autism symptoms, and fewer challenging behaviours²³¹. In addition, more recent research suggests that women with autism may have a more difficult time maintaining employment positions²³², and are more likely to ‘camouflage’ their autism symptoms than men, which can lead to mental health challenges²³³.

[H3] Subjective QOL. Meta-analysis have suggested that across the lifespan, subjective QOL tends to be lower among individuals with autism compared to typically-developing peers²³⁴, but is often more positive than indicators of objective QOL^{229,235}. Predictors of subjective QOL tend to be inconsistent across studies, except for perceived stress and supports, the latter of which encompasses services, family and social support^{236–238}.

[H2] Self-advocate perspective

It is clear that autism has heterogeneous outcomes and biological underpinnings; what is less clear-cut are the differing and nuanced views of autistic people regarding how autism should be approached and researched (Box 3, Autistica²³⁹, see also Ontario Brain Institute²⁴⁰). Indeed, some people with a diagnosis see autism as being a fundamental part of their identity whereas other people do not. In addition, many people feel that social change is required²⁴¹, whereas other individuals want therapies to meet a range of their needs²⁴². The key is respect for a variety of views and ultimately respect for autistic people. Researchers can demonstrate respect by considering how autism as a topic is distinct from, for example, cancer. To this end, terms like ‘disease’ are inappropriate and are scientifically inaccurate when referring to autism. Ultimately, active participation in the design, implementation and interpretation of research studies, clear consideration of research ethics and the consequences of research involvement and broad consultation of autistic people in research is key to authentically addressing the substantial inequalities autistic people face as a group and ensuring they live long, healthy, happy lives.

[H2] Family perspectives

Families of people with autism are also heterogeneous, yet, as a group, they experience lower QOL than families with a member with other neurodevelopmental conditions, even before receiving the formal diagnosis²⁴³. For this reason, it is essential that parents, other family members, clinicians, educators, and the entire external support system coalesce around common goals for outcomes whilst accessing and

maximizing resources for the betterment of the child and family. Parents are typically at the centre of this support network and carry much of the responsibility of direct care, coordination and advocacy, over and above typical parental responsibilities^{244,245}. The exact parental roles are dependent on the child's strengths and challenges, and frequently shift over time (Fig. 6). During this process, it is important that parents maintain motivation by setting realistic goals and tracking progress to experience the many achievements that their loved one with autism can attain.

Effective parents often work closely with experienced providers who can track development of the child with autism and can provide guidance on next actions²⁴⁶. Early in childhood, this role includes identifying and engaging with early and school-based interventions. It is never too early for parents to begin planning for the adult transition process, including (dependent on the person with autism's capacity) promoting self-advocacy, preparation for life after secondary education, vocational training and employment supports, living needs, community participation, and long-term financial considerations. During adulthood, for cognitively-able adults, parental roles might shift to more traditional relationships²⁴⁷, whereas for those with cognitive disability, parental caregiving often continues and culminates in planning for late life needs²⁴⁸. Although the journey can be challenging, for many parents, it can be incredibly rewarding and a source of life meaning.

Many parents recognize the need to give back to the community through research. Accordingly, it is crucial that researchers foster this desire carefully, communicating with parents to ensure that any potential immediate or future risks or benefits are clear. Even if the study period is brief, in many cases, the goal should be to develop a positive longer-term relationship, as this can lead to parents and people with autism continually re-engaging in and developing positive feelings about the research process.

[H1] Outlook

Autism research has substantially expanded in the past 50 years, particularly the past 20 years, as reflected in the websites listed in Box 4. Although it seems unlikely that the incidence of autism is truly rising at the rate suggested in administrative prevalence studies, these data have increased awareness and the numbers of diagnosed children in schools and clinics, although adult services and recognition run far behind. The lives of people with autism diagnoses have improved at least in some high-income countries, with a greater proportion of children using some language²⁴⁹, more adults with educational qualifications and less institutionalization²⁴⁹, although the changing nature of diagnoses has to be considered when interpreting historical trends. Some risk factors for autism have been identified (such as increased parental age, birth trauma and a positive family history) which has implications at least for more careful follow-up. In addition, the genetics of autism has yielded surprising discoveries with substantial implications for heritable neurodevelopmental disorders, such as ADHD, language delay and named syndromes associated with profound intellectual disability. The perceived value of routine genetic screening for autism diagnosis is disputed, autism, with American medical academies strongly in favor whereas those in other countries much more selective. Studies of brain structure and function have added similarly intriguing findings that are just beginning to be integrated into both developmental and more mechanistic models of behaviour with possible targets or markers for change. Despite the intellectual contribution of these studies to research, at this point, neither EEG nor imaging are recommended as part of standard practice for diagnosis of autism but can be used for other

neurological indicators (such as if there are concerns beyond autism symptoms that merit an EEG or imaging). In this field, replication of findings across sites and even within individuals, as well as larger samples through collaboration are the promise of the future.

One way of bringing the three themes of mechanisms, heterogeneity and outcomes of autism together is to consider the trajectories of this disorder over time (Fig. 7), and how knowledge of these trajectories can contribute to investigations of the biological and cognitive underpinnings of autism, and how treatments and supports could make the lives of children and adults with autism more positive.

In terms of mechanisms, despite earlier hopes for simple genetic explanations of autism, instead, we have identified many single gene germline loss of function point mutations yielding some initial models of disruption in very basic molecular patterns, as well common genes with small effects that are just beginning to emerge²⁹. Attempts to study genes-first have shown heterogeneity even within highly specific CNVs, with a few exceptions. In addition, hope exists that genetically based interventions for autism may be possible, although this will likely involve much further research. Data from genetic approaches that might yield targeted genetic interventions may be most relevant to rare, severe neurodevelopmental difficulties in general rather than autism as a specific entity. With more information about the differing developmental trajectories of autism, more continuous measures of symptoms and measures of language and intellectual function, behavioural phenotypes and changes over time can be quantified across different neurobiologically defined subgroups. This approach could potentially identify different 'routes' to different outcomes, whether autism or not, and could have a practical benefit in terms of selecting and monitoring appropriate treatments. In addition, with the heterogeneity of autism, our growing understanding of mechanisms, be they causal or mechanisms for change, needs to be linked to trajectories in development and not be considered as static²⁵⁰. Researchers modelling autism in other species might find the incorporation of early developmental manifestations, such as regressions or motor delays, more tractable than the current focus on autism-related social communication symptoms seen in humans. With collaborations and studies of sufficient sample sizes, investigators have begun to focus on findings within different developmental periods that could provide insight into trajectories and targets for intervention. Thus, more study of the development of autism both in studies of human behaviours and in animal models might have an effect on the identification and treatment of autism as a neurodevelopmental disorder. Prospective studies, including epidemiological and direct behavioural work across developmental periods, moving beyond very young children to later childhood, adolescence, and adulthood are needed.

Similarly, limited findings about adult development and patterns that lead into autism (Figs 5 and 7), call for measurement of different outcomes that respect individual differences in autistic people and in families (Box 3). By young adulthood, available supports for places to live, employment and mental health services are needed for individuals who have a range of skill levels, with supports not always well matched to the needs of individuals; however, comparisons of treatments or treatment intensities have not historically been made, even though they are continually called for. The types and specific goals of treatments differ greatly for autistic people who are verbally fluent versus those who have difficulty speaking for themselves, such that alternative systems need to be in place that take into account co-occurring conditions, strengths, preferences and challenges. More studies of well-defined, more homogeneous subgroups of autistic children and adults over time would provide different and more useful information about real-life issues, as in Table 2 than large-scale surveys of very heterogeneous samples²⁵¹.

Progress in the biology of more generally defined neurodevelopmental disorders may have the greatest yield for children with autism in their early years. Clinical trials that compare known treatments (both psychosocial and biological), with new ones and treatment as usual would allow us to build on previous findings in a more meaningful way and begin to address the priorities listed in Box 3, which strikingly, are seldom priorities in autism research. To move from science to practice including evaluation and treatment, autism researchers need to find a way to select and fund studies of more mundane, but critical evidence gaps in understanding heterogeneity, mechanisms of change and outcome that affect practice in any circumstance, not just internationally, within academic systems that reward creativity and novelty. Unique methodologies, including the baby sibling studies, accumulation of large data sets (such as ABIDE, and the Simons Simplex Collection (SSC)), prospective epidemiological studies and mechanistic studies of intermediate biomarkers may begin to bring together information from molecular to pathophysiological to cognitive and behavioural levels. However, for now, as for other neurodevelopmental and psychiatric disorders including schizophrenia²⁵², the distance between science and practice remains great, and the amount of research that attempts to address solvable problems for autistic people alive today and their families remains modest.

References

1. Lord, C. *et al.* Autism From 2 to 9 Years of Age. *Arch. Gen. Psychiatry* **63**, 694 (2006).
- This paper clearly establishes that autism was a stable diagnosis (as a spectrum) beginning at least by age 2. The paper also established parent interview and clinician observation as predictive of autism at age 9. Finally, it was the first paper that showed that the specific DSM-IV-TR diagnoses were unstable across childhood but that the instability was almost all shifting across categories not outside the spectrum.**
2. Risi, S. *et al.* Combining Information From Multiple Sources in the Diagnosis of Autism Spectrum Disorders. *J. Am. Acad. Child Adolesc. Psychiatry* **45**, 1094–1103 (2006).
3. Loomes, R., Hull, L. & Mandy, W. P. L. What Is the Male-to-Female Ratio in Autism Spectrum Disorder? A Systematic Review and Meta-Analysis. *J. Am. Acad. Child Adolesc. Psychiatry* **56**, 466–474 (2017).
4. Brugha, T. S. *et al.* Epidemiology of autism in adults across age groups and ability levels. *Br. J. Psychiatry* **209**, 498–503 (2016).
- This paper uses active case-finding to provide representative estimates of the prevalence of ASD and demonstrated that rates of ASD in men and women were equivalent in adults with moderate to profound intellectual disability.**

- 860 5. Brugha, T., Bankart, J., McManus, S. & Gullon-Scott, F. CDC autism rate: misplaced reliance on
861 passive sampling? *The Lancet* **392**, 732–733 (2018).
- 862 6. Baxter, A. J. *et al.* The epidemiology and global burden of autism spectrum disorders. *Psychol.*
863 *Med.* **45**, 601–613 (2014).
- 864 7. Elsabbagh, M. *et al.* Global Prevalence of Autism and Other Pervasive Developmental Disorders:
865 Global epidemiology of autism. *Autism Res.* **5**, 160–179 (2012).
- 866 8. Magnusson, C. *et al.* Migration and autism spectrum disorder: population-based study. *Br. J.*
867 *Psychiatry* **201**, 109–115 (2012).
- 868 9. Goodman, R. & Richards, H. Child and Adolescent Psychiatric Presentations of Second-Generation
869 Afro-Caribbeans in Britain. *Br. J. Psychiatry* **167**, 362–369 (1995).
- 870 10. Dyches, T. T., Wilder, L. K., Sudweeks, R. R., Obiakor, F. E. & Algozzine, B. Multicultural Issues in
871 Autism. *J. Autism Dev. Disord.* **34**, 211–222 (2004).
- 872 11. Keen, D. V., Reid, F. D. & Arnone, D. Autism, ethnicity and maternal immigration. *Br. J. Psychiatry*
873 **196**, 274–281 (2010).
- 874 12. McManus S, Bebbington P, Jenkins R & Brugha T. *Mental Health and Wellbeing in England: Adult*
875 *Psychiatric Morbidity Survey 2014.* (2016).
- 876 13. James, S. L. *et al.* Global, regional, and national incidence, prevalence, and years lived with
877 disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic
878 analysis for the Global Burden of Disease Study 2017. *The Lancet* **392**, 1789–1858 (2018).
- 879 14. Marcheselli, F & *et al.* *Mental health of children and young people in England, 2017: Autism*
880 *spectrum, eating and other less common disorders.* (2018).
- 881 15. Brugha, T. C & *et al.* *Autism spectrum disorder, adult psychiatric morbidity survey 2014.* (2014).

- 882 16. Lundstrom, S., Reichenberg, A., Anckarsater, H., Lichtenstein, P. & Gillberg, C. Autism phenotype
883 versus registered diagnosis in Swedish children: prevalence trends over 10 years in general
884 population samples. *BMJ* **350**, h1961–h1961 (2015).
- 885 17. Tromans, S., Chester, V., Kiani, R., Alexander, R. & Brugha, T. The Prevalence of Autism Spectrum
886 Disorders in Adult Psychiatric Inpatients: A Systematic Review. *Clin. Pract. Epidemiol. Ment. Health*
887 **14**, 177–187 (2018).
- 888 18. Modabbernia, A., Velthorst, E. & Reichenberg, A. Environmental risk factors for autism: an
889 evidence-based review of systematic reviews and meta-analyses. *Mol. Autism* **8**, (2017).
- 890 19. Wu, S. *et al.* Advanced parental age and autism risk in children: a systematic review and meta-
891 analysis. *Acta Psychiatr. Scand.* **135**, 29–41 (2016).
- 892 20. Taylor, L. E., Swerdfeger, A. L. & Eslick, G. D. Vaccines are not associated with autism: An evidence-
893 based meta-analysis of case-control and cohort studies. *Vaccine* **32**, 3623–3629 (2014).
- 894 21. Lai, M.-C., Lombardo, M. V. & Baron-Cohen, S. Autism. *The Lancet* **383**, 896–910 (2014).
- 895 22. Velikonja, T., Fett, A.-K. & Velthorst, E. Patterns of Nonsocial and Social Cognitive Functioning in
896 Adults With Autism Spectrum Disorder: A Systematic Review and Meta-analysis. *JAMA Psychiatry*
897 **76**, 135 (2019).
- 898 23. McNally Keehn, R. H., Lincoln, A. J., Brown, M. Z. & Chavira, D. A. The Coping Cat Program for
899 Children with Anxiety and Autism Spectrum Disorder: A Pilot Randomized Controlled Trial. *J.*
900 *Autism Dev. Disord.* **43**, 57–67 (2013).
- 901 24. Jones, E. J. H., Gliga, T., Bedford, R., Charman, T. & Johnson, M. H. Developmental pathways to
902 autism: A review of prospective studies of infants at risk. *Neurosci. Biobehav. Rev.* **39**, 1–33 (2014).
- 903 25. Ozonoff, S. *et al.* Recurrence Risk for Autism Spectrum Disorders: A Baby Siblings Research
904 Consortium Study. *Pediatrics* **128**, e488-95 (2011).

- 905 26. Jones, R. M. & Lord, C. Diagnosing autism in neurobiological research studies. *Behav. Brain Res.*
 906 **251**, 113–124 (2013).
- 907 27. Johnson, M. H. Autism: Demise of the Innate Social Orienting Hypothesis. *Curr. Biol.* **24**, R30–R31
 908 (2014).
- 909 28. Johnson, M. H., Jones, E. J. H. & Gliga, T. Brain adaptation and alternative developmental
 910 trajectories. *Dev. Psychopathol.* **27**, 425–442 (2015).
- 911 29. The Lancet Psychiatry. Of mice and mental health. *Lancet Psychiatry* **6**, 877 (2019).
- 912 30. Nelson, C. A. *et al.* An integrative, multidisciplinary approach to the study of brain-behavior
 913 relations in the context of typical and atypical development. *Dev. Psychopathol.* **14**, 499–520
 914 (2002).
- 915 31. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. *Nat.*
 916 *Genet.* **45**, 984–994 (2013).
- 917 32. Gaugler, T. *et al.* Most genetic risk for autism resides with common variation. *Nat. Genet.* **46**, 881–
 918 885 (2014).
- 919 33. Wang, K., Gaitsch, H., Poon, H., Cox, N. J. & Rzhetsky, A. Classification of common human diseases
 920 derived from shared genetic and environmental determinants. *Nat. Genet.* **49**, 1319–1325 (2017).
- 921 34. Sanders, S. J. *et al.* Insights into Autism Spectrum Disorder Genomic Architecture and Biology from
 922 71 Risk Loci. *Neuron* **87**, 1215–1233 (2015).
- 923 35. Satterstrom, F. K. *et al.* Large-scale exome sequencing study implicates both developmental and
 924 functional changes in the neurobiology of autism. *bioRxiv* (2019) doi:10.1101/484113.
- 925 36. Sanders, S. J. *et al.* De novo mutations revealed by whole-exome sequencing are strongly
 926 associated with autism. *Nature* **485**, 237–241 (2012).
- 927 37. Neale, B. M. *et al.* Patterns and rates of exonic de novo mutations in autism spectrum disorders.
 928 *Nature* **485**, 242–245 (2012).

- 929 38. O’Roak, B. J. *et al.* Sporadic autism exomes reveal a highly interconnected protein network of de
930 novo mutations. *Nature* **485**, 246–250 (2012).
- 931 39. Sanders, S. J. *et al.* Multiple Recurrent De Novo CNVs, Including Duplications of the 7q11.23
932 Williams Syndrome Region, Are Strongly Associated with Autism. *Neuron* **70**, 863–885 (2011).
- 933 40. Levy, D. *et al.* Rare De Novo and Transmitted Copy-Number Variation in Autistic Spectrum
934 Disorders. *Neuron* **70**, 886–897 (2011).
- 935 41. Sebat, J. *et al.* Strong Association of De Novo Copy Number Mutations with Autism. *Science* **316**,
936 445–449 (2007).
- 937 **This paper was the first to focus explicitly on simplex autism and show the importance of de novo**
938 **CNVs in simplex cases, versus familial cases, versus controls.**
- 939 42. Autism Spectrum Disorder Working Group of the Psychiatric Genomics Consortium *et al.*
940 Identification of common genetic risk variants for autism spectrum disorder. *Nat. Genet.* **51**, 431–
941 444 (2019).
- 942 43. Willsey, J. *et al.* De Novo Coding Variants Are Strongly Associated with Tourette Syndrome. *Eur.*
943 *Neuropsychopharmacol.* **29**, S737 (2019).
- 944 44. Epi4K Consortium. Epi4K: Gene discovery in 4,000 genomes. *Epilepsia* **53**, 1457–1467 (2012).
- 945 45. Jamain, S. *et al.* Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are
946 associated with autism. *Nat. Genet.* **34**, 27–29 (2003).
- 947 **This was the first paper to show a de novo loss of function mutation in a synaptic gene associated**
948 **with non-syndromic ASD and really was a harbinger for so many of the findings that came after.**
- 949 46. Iossifov, I. *et al.* The contribution of de novo coding mutations to autism spectrum disorder.
950 *Nature* **515**, 216–221 (2014).
- 951 47. De Rubeis, S. *et al.* Synaptic, transcriptional and chromatin genes disrupted in autism. *Nature* **515**,
952 209–215 (2014).

- 953 48. Sestan, N. & State, M. W. Lost in Translation: Traversing the Complex Path from Genomics to
954 Therapeutics in Autism Spectrum Disorder. *Neuron* **100**, 406–423 (2018).
- 955 49. State, M. W. & Sestan, N. The Emerging Biology of Autism Spectrum Disorders. *Science* **337**, 1301–
956 1303 (2012).
- 957 50. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108
958 schizophrenia-associated genetic loci. *Nature* **511**, 421–427 (2014).
- 959 51. Devlin, B. & Scherer, S. W. Genetic architecture in autism spectrum disorder. *Curr. Opin. Genet.*
960 *Dev.* **22**, 229–237 (2012).
- 961 52. de la Torre-Ubieta, L., Won, H., Stein, J. L. & Geschwind, D. H. Advancing the understanding of
962 autism disease mechanisms through genetics. *Nat. Med.* **22**, 345–361 (2016).
- 963 53. *SFARI Gene Website*. <https://gene.sfari.org/>.
- 964 54. Parikshak, N. N. *et al.* Integrative Functional Genomic Analyses Implicate Specific Molecular
965 Pathways and Circuits in Autism. *Cell* **155**, 1008–1021 (2013).
- 966 55. Ben-David, E. & Shifman, S. Combined analysis of exome sequencing points toward a major role for
967 transcription regulation during brain development in autism. *Mol. Psychiatry* **18**, 1054–1056
968 (2012).
- 969 56. Willsey, A. J. *et al.* Coexpression Networks Implicate Human Midfetal Deep Cortical Projection
970 Neurons in the Pathogenesis of Autism. *Cell* **155**, 997–1007 (2013).
- 971 57. Pinto, D. *et al.* Functional impact of global rare copy number variation in autism spectrum
972 disorders. *Nature* **466**, 368–372 (2010).
- 973 58. Gilman, S. R. *et al.* Rare De Novo Variants Associated with Autism Implicate a Large Functional
974 Network of Genes Involved in Formation and Function of Synapses. *Neuron* **70**, 898–907 (2011).
- 975 59. Fuccillo, M. V. Striatal Circuits as a Common Node for Autism Pathophysiology. *Front. Neurosci.* **10**,
976 (2016).

- 977 60. Velmeshev, D. *et al.* Single-cell genomics identifies cell type–specific molecular changes in autism.
978 *Science* **364**, 685–689 (2019).
- 979 61. Mendell, J. R. *et al.* Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. *N. Engl. J.*
980 *Med.* **377**, 1713–1722 (2017).
- 981 62. Mercuri, E. *et al.* Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. *N. Engl.*
982 *J. Med.* **378**, 625–635 (2018).
- 983 63. Matharu, N. *et al.* CRISPR-mediated activation of a promoter or enhancer rescues obesity caused
984 by haploinsufficiency. *Science* **363**, eaau0629 (2019).
- 985 64. Abudayyeh, O. O. *et al.* RNA targeting with CRISPR–Cas13. *Nature* **550**, 280–284 (2017).
- 986 65. Power, J. D. *et al.* Customized head molds reduce motion during resting state fMRI scans.
987 *NeuroImage* **189**, 141–149 (2019).
- 988 66. Solso, S. *et al.* Diffusion Tensor Imaging Provides Evidence of Possible Axonal Overconnectivity in
989 Frontal Lobes in Autism Spectrum Disorder Toddlers. *Biol. Psychiatry* **79**, 676–684 (2016).
- 990 67. Clements, C. C. *et al.* Evaluation of the Social Motivation Hypothesis of Autism. *JAMA Psychiatry*
991 **75**, 797 (2018).
- 992 68. Ecker, C. Brain Anatomy and Its Relationship to Behavior in Adults With Autism Spectrum Disorder.
993 *Arch. Gen. Psychiatry* **69**, 195 (2012).
- 994 69. Langen, M. *et al.* Changes in the Development of Striatum Are Involved in Repetitive Behavior in
995 Autism. *Biol. Psychiatry* **76**, 405–411 (2014).
- 996 70. Elsabbagh, M. & Johnson, M. H. Autism and the Social Brain: The First-Year Puzzle. *Biol. Psychiatry*
997 **80**, 94–99 (2016).
- 998 71. Courchesne, E. *et al.* Unusual brain growth patterns in early life in patients with autistic disorder:
999 An MRI study. *Neurology* **57**, 245–254 (2001).

- 1000 72. Hazlett, H. C. *et al.* Magnetic Resonance Imaging and Head Circumference Study of Brain Size in
 1001 Autism. *Arch. Gen. Psychiatry* **62**, 1366 (2005).
- 1002 73. Wolff, J. J. *et al.* Differences in White Matter Fiber Tract Development Present From 6 to 24
 1003 Months in Infants With Autism. *Am. J. Psychiatry* **169**, 589–600 (2012).
- 1004 74. Hazlett, H. C. *et al.* Early brain development in infants at high risk for autism spectrum disorder.
 1005 *Nature* **542**, 348–351 (2017).
- 1006 **This seminal paper, through careful recruitment and methodology was the first to show significant**
 1007 **early differences that may contribute to our understanding of developmental features in neural**
 1008 **structure and circuits.**
- 1009 75. Wolff, J. J. *et al.* Neural circuitry at age 6 months associated with later repetitive behavior and
 1010 sensory responsiveness in autism. *Mol. Autism* **8**, (2017).
- 1011 76. Emerson, R. W. *et al.* Functional neuroimaging of high-risk 6-month-old infants predicts a diagnosis
 1012 of autism at 24 months of age. *Sci. Transl. Med.* **9**, eaag2882 (2017).
- 1013 77. Smith, E. *et al.* Cortical thickness change in autism during early childhood: CT in Early Childhood
 1014 ASD. *Hum. Brain Mapp.* **37**, 2616–2629 (2016).
- 1015 78. Uddin, L. Q., Dajani, D. R., Voorhies, W., Bednarz, H. & Kana, R. K. Progress and roadblocks in the
 1016 search for brain-based biomarkers of autism and attention-deficit/hyperactivity disorder. *Transl.*
 1017 *Psychiatry* **7**, e1218–e1218 (2017).
- 1018 79. Herringshaw, A. J., Ammons, C. J., DeRamus, T. P. & Kana, R. K. Hemispheric differences in
 1019 language processing in autism spectrum disorders: A meta-analysis of neuroimaging studies.
 1020 *Autism Res.* **9**, 1046–1057 (2016).
- 1021 80. He, Y., Byrge, L. & Kennedy, D. P. Non-replication of functional connectivity differences in autism
 1022 spectrum disorder across multiple sites and denoising strategies. *bioRxiv* (2019)
 1023 doi:10.1101/640797.

- 1024 81. Lawrence, K. E., Hernandez, L. M., Bookheimer, S. Y. & Dapretto, M. Atypical longitudinal
1025 development of functional connectivity in adolescents with autism spectrum disorder. *Autism Res.*
1026 **12**, 53–65 (2018).
- 1027 82. Plitt, M., Barnes, K. A., Wallace, G. L., Kenworthy, L. & Martin, A. Resting-state functional
1028 connectivity predicts longitudinal change in autistic traits and adaptive functioning in autism. *Proc.*
1029 *Natl. Acad. Sci.* **112**, E6699–E6706 (2015).
- 1030 83. Di Martino, A. *et al.* The autism brain imaging data exchange: towards a large-scale evaluation of
1031 the intrinsic brain architecture in autism. *Mol. Psychiatry* **19**, 659–667 (2013).
- 1032 84. Doyle-Thomas, K. A. R. *et al.* Atypical functional brain connectivity during rest in autism spectrum
1033 disorders. *Ann. Neurol.* **77**, 866–876 (2015).
- 1034 85. Supekar, K. *et al.* Brain Hyperconnectivity in Children with Autism and its Links to Social Deficits.
1035 *Cell Rep.* **5**, 738–747 (2013).
- 1036 86. Dajani, D. R. & Uddin, L. Q. Local brain connectivity across development in autism spectrum
1037 disorder: A cross-sectional investigation. *Autism Res.* **9**, 43–54 (2015).
- 1038 87. Hull, J. V. *et al.* Resting-State Functional Connectivity in Autism Spectrum Disorders: A Review.
1039 *Front. Psychiatry* **7**, (2017).
- 1040 88. Lombardo, M. V. *et al.* Different Functional Neural Substrates for Good and Poor Language
1041 Outcome in Autism. *Neuron* **86**, 567–577 (2015).
- 1042 89. Carlisi, C. O. *et al.* Disorder-Specific and Shared Brain Abnormalities During Vigilance in Autism and
1043 Obsessive-Compulsive Disorder. *Biol. Psychiatry Cogn. Neurosci. Neuroimaging* **2**, 644–654 (2017).
- 1044 90. Alaerts, K., Swinnen, S. P. & Wenderoth, N. Sex differences in autism: a resting-state fMRI
1045 investigation of functional brain connectivity in males and females. *Soc. Cogn. Affect. Neurosci.* **11**,
1046 1002–1016 (2016).

- 1047 91. Kirkovski, M., Enticott, P. G., Hughes, M. E., Rossell, S. L. & Fitzgerald, P. B. Atypical Neural Activity
1048 in Males But Not Females with Autism Spectrum Disorder. *J. Autism Dev. Disord.* **46**, 954–963
1049 (2016).
- 1050 92. Venkataraman, A. *et al.* Pivotal response treatment prompts a functional rewiring of the brain
1051 among individuals with autism spectrum disorder. *NeuroReport* **27**, 1081–1085 (2016).
- 1052 93. Levisohn, P. M. The autism-epilepsy connection. *Epilepsia* **48**, 33–35 (2007).
- 1053 94. Cantor, D. S., Thatcher, R. W., Hrybyk, M. & Kaye, H. Computerized EEG analyses of autistic
1054 children. *J. Autism Dev. Disord.* **16**, 169–187 (1986).
- 1055 95. Lefebvre, A. *et al.* Alpha Waves as a Neuromarker of Autism Spectrum Disorder: The Challenge of
1056 Reproducibility and Heterogeneity. *Front. Neurosci.* **12**, (2018).
- 1057 96. Tierney, A. L., Gabard-Durnam, L., Vogel-Farley, V., Tager-Flusberg, H. & Nelson, C. A.
1058 Developmental Trajectories of Resting EEG Power: An Endophenotype of Autism Spectrum
1059 Disorder. *PLoS ONE* **7**, e39127 (2012).
- 1060 97. Oberman, L. M. *et al.* EEG evidence for mirror neuron dysfunction in autism spectrum disorders.
1061 *Cogn. Brain Res.* **24**, 190–198 (2005).
- 1062 98. Fan, Y.-T., Decety, J., Yang, C.-Y., Liu, J.-L. & Cheng, Y. Unbroken mirror neurons in autism spectrum
1063 disorders. *J. Child Psychol. Psychiatry* **51**, 981–988 (2010).
- 1064 99. Southgate, V. & de C. Hamilton, A. F. Unbroken mirrors: challenging a theory of Autism. *Trends*
1065 *Cogn. Sci.* **12**, 225–229 (2008).
- 1066 100. Bernier, R., Aaronson, B. & McPartland, J. The role of imitation in the observed heterogeneity in
1067 EEG mu rhythm in autism and typical development. *Brain Cogn.* **82**, 69–75 (2013).
- 1068 101. Raymaekers, R., Wiersema, J. R. & Roeyers, H. EEG study of the mirror neuron system in children
1069 with high functioning autism. *Brain Res.* **1304**, 113–121 (2009).

- 1070 102. Dumas, G., Soussignan, R., Hugueville, L., Martinerie, J. & Nadel, J. Revisiting mu suppression in
 1071 autism spectrum disorder. *Brain Res.* **1585**, 108–119 (2014).
- 1072 **Paper replicating the mu suppression deficits in autism during action observation but questioning**
 1073 **through high-density spectral analyses and sources reconstruction its previously drawn relation to the**
 1074 **MNS.**
- 1075 103. Marco, E. J., Hinkley, L. B. N., Hill, S. S. & Nagarajan, S. S. Sensory Processing in Autism: A Review of
 1076 Neurophysiologic Findings. *Pediatr. Res.* **69**, 48R–54R (2011).
- 1077 104. Schwartz, S., Shinn-Cunningham, B. & Tager-Flusberg, H. Meta-analysis and systematic review of
 1078 the literature characterizing auditory mismatch negativity in individuals with autism. *Neurosci.*
 1079 *Biobehav. Rev.* **87**, 106–117 (2018).
- 1080 105. Kang, E. *et al.* Atypicality of the N170 Event-Related Potential in Autism Spectrum Disorder: A
 1081 Meta-analysis. *Biol. Psychiatry Cogn. Neurosci. Neuroimaging* **3**, 657–666 (2018).
- 1082 106. Bonnet-Brilhault, F. *et al.* GABA/Glutamate synaptic pathways targeted by integrative genomic and
 1083 electrophysiological explorations distinguish autism from intellectual disability. *Mol. Psychiatry* **21**,
 1084 411–418 (2015).
- 1085 107. Schilbach, L. Towards a second-person neuropsychiatry. *Philos. Trans. R. Soc. B Biol. Sci.* **371**,
 1086 20150081 (2016).
- 1087 **Review supporting that psychiatric disorders are more commonly characterized by impairments of**
 1088 **social interaction rather than social observation, and advocating for an interactive turn in**
 1089 **neuropsychiatry.**
- 1090 108. Barraza, P. *et al.* Implementing EEG hyperscanning setups. *MethodsX* **6**, 428–436 (2019).
- 1091 109. Dumas, G., de Guzman, G. C., Tognoli, E. & Kelso, J. A. S. The human dynamic clamp as a paradigm
 1092 for social interaction. *Proc. Natl. Acad. Sci.* **111**, E3726–E3734 (2014).
- 1093 110. Jones, E. J. H. *et al.* Reduced engagement with social stimuli in 6-month-old infants with later
 1094 autism spectrum disorder: a longitudinal prospective study of infants at high familial risk. *J.*
 1095 *Neurodev. Disord.* **8**, (2016).

- 1096 111. Ciarrusta, J. *et al.* Social Brain Functional Maturation in Newborn Infants With and Without a
 1097 Family History of Autism Spectrum Disorder. *JAMA Netw. Open* **2**, e191868 (2019).
- 1098 112. Levin, A. R., Varcin, K. J., O’Leary, H. M., Tager-Flusberg, H. & Nelson, C. A. EEG power at 3 months
 1099 in infants at high familial risk for autism. *J. Neurodev. Disord.* **9**, (2017).
- 1100 113. Kolesnik, A. *et al.* Increased cortical reactivity to repeated tones at 8 months in infants with later
 1101 ASD. *Transl. Psychiatry* **9**, (2019).
- 1102 114. Rippon, G., Brock, J., Brown, C. & Boucher, J. Disordered connectivity in the autistic brain:
 1103 Challenges for the ‘new psychophysiology’. *Int. J. Psychophysiol.* **63**, 164–172 (2007).
- 1104 115. Rosenberg, A., Patterson, J. S. & Angelaki, D. E. A computational perspective on autism. *Proc. Natl.*
 1105 *Acad. Sci.* **112**, 9158–9165 (2015).
- 1106 116. Masuda, F. *et al.* Motor cortex excitability and inhibitory imbalance in autism spectrum disorder
 1107 assessed with transcranial magnetic stimulation: a systematic review. *Transl. Psychiatry* **9**, (2019).
- 1108 117. O’Reilly, C., Lewis, J. D. & Elsabbagh, M. Is functional brain connectivity atypical in autism? A
 1109 systematic review of EEG and MEG studies. *PLOS ONE* **12**, e0175870 (2017).
- 1110 118. Khan, S. *et al.* Somatosensory cortex functional connectivity abnormalities in autism show opposite
 1111 trends, depending on direction and spatial scale. *Brain* **138**, 1394–1409 (2015).
- 1112 119. Chen, H., Nomi, J. S., Uddin, L. Q., Duan, X. & Chen, H. Intrinsic functional connectivity variance and
 1113 state-specific under-connectivity in autism. *Hum. Brain Mapp.* **38**, 5740–5755 (2017).
- 1114 120. Catarino, A., Churches, O., Baron-Cohen, S., Andrade, A. & Ring, H. Atypical EEG complexity in
 1115 autism spectrum conditions: A multiscale entropy analysis. *Clin. Neurophysiol.* **122**, 2375–2383
 1116 (2011).
- 1117 121. Engemann, D. A. *et al.* Robust EEG-based cross-site and cross-protocol classification of states of
 1118 consciousness. *Brain* **141**, 3179–3192 (2018).
- 1119 122. Estimating the reproducibility of psychological science. *Science* **349**, aac4716–aac4716 (2015).

- 1120 123. Lord, C *et al.* *Autism diagnostic observation schedule: ADOS-2*. (2012).
- 1121 124. Regier, D. A. *et al.* DSM-5 Field Trials in the United States and Canada, Part II: Test-Retest Reliability
1122 of Selected Categorical Diagnoses. *Am. J. Psychiatry* **170**, 59–70 (2013).
- 1123 125. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders, Fifth*
1124 *Edition*. (American Psychiatric Association, 2013).
- 1125 126. WHO. *International classification of diseases for mortality and morbidity statistics (11th Revision)*.
1126 <https://icd.who.int/browse11/l-m/en> (2018).
- 1127 127. Constantino, J. N. & Charman, T. Diagnosis of autism spectrum disorder: reconciling the syndrome,
1128 its diverse origins, and variation in expression. *Lancet Neurol.* **15**, 279–291 (2016).
- 1129 128. Lord, C. A Multisite Study of the Clinical Diagnosis of Different Autism Spectrum Disorders. *Arch.*
1130 *Gen. Psychiatry* **69**, 306 (2012).
- 1131 129. Miller, J. N. & Ozonoff, S. The external validity of Asperger disorder: lack of evidence from the
1132 domain of neuropsychology. *J. Abnorm. Psychol.* **109**, 227–238 (2000).
- 1133 130. *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition*. (American Psychiatric
1134 Association).
- 1135 131. Green, D., Chandler, S., Charman, T., Simonoff, E. & Baird, G. Brief Report: DSM-5 Sensory
1136 Behaviours in Children With and Without an Autism Spectrum Disorder. *J. Autism Dev. Disord.* **46**,
1137 3597–3606 (2016).
- 1138 132. Ozonoff, S. *et al.* Diagnosis of Autism Spectrum Disorder After Age 5 in Children Evaluated
1139 Longitudinally Since Infancy. *J. Am. Acad. Child Adolesc. Psychiatry* **57**, 849–857.e2 (2018).
- 1140 133. Russell, G., Steer, C. & Golding, J. Social and demographic factors that influence the diagnosis of
1141 autistic spectrum disorders. *Soc. Psychiatry Psychiatr. Epidemiol.* **46**, 1283–1293 (2010).

- 1142 134. Charman, T. & Gotham, K. Measurement Issues: Screening and diagnostic instruments for autism
 1143 spectrum disorders - lessons from research and practise. *Child Adolesc. Ment. Health* **18**, 52–63
 1144 (2012).
- 1145 135. Ashwood, K. L., Buitelaar, J., Murphy, D., Spooren, W. & Charman, T. European clinical network:
 1146 autism spectrum disorder assessments and patient characterisation. *Eur. Child Adolesc. Psychiatry*
 1147 **24**, 985–995 (2015).
- 1148 136. Rutter, M, LeCouteur, A & Lord, C. *Autism diagnostic interview-revised (ADI-R)*. (Western
 1149 Psychological Services, 2003).
- 1150 137. Durkin, M. S. *et al.* Autism screening and diagnosis in low resource settings: Challenges and
 1151 opportunities to enhance research and services worldwide. *Autism Res.* **8**, 473–476 (2015).
- 1152 **This is a position paper highlighting challenges to translating knowledge on better awareness,**
 1153 **understanding, identification, diagnosis (and then treatments) from the past two decades of clinical**
 1154 **research in HICs into LMICs**
- 1155 138. Baird, G. *et al.* Prevalence of disorders of the autism spectrum in a population cohort of children in
 1156 South Thames: the Special Needs and Autism Project (SNAP). *The Lancet* **368**, 210–215 (2006).
- 1157 139. Luyster, R. *et al.* The Autism Diagnostic Observation Schedule—Toddler Module: A New Module of
 1158 a Standardized Diagnostic Measure for Autism Spectrum Disorders. *J. Autism Dev. Disord.* **39**,
 1159 1305–1320 (2009).
- 1160 140. de Vries, P. J. Thinking globally to meet local needs. *Curr. Opin. Neurol.* **29**, 130–136 (2016).
- 1161 141. Georgiades, S., Bishop, S. L. & Frazier, T. Editorial Perspective: Longitudinal research in autism -
 1162 introducing the concept of ‘chronogeneity’. *J. Child Psychol. Psychiatry* **58**, 634–636 (2017).
- 1163 142. Fountain, C., Winter, A. S. & Bearman, P. S. Six Developmental Trajectories Characterize Children
 1164 With Autism. *Pediatrics* **129**, e1112–e1120 (2012).
- 1165 143. Kim, S. H. *et al.* Variability in Autism Symptom Trajectories Using Repeated Observations From 14
 1166 to 36 Months of Age. *J. Am. Acad. Child Adolesc. Psychiatry* **57**, 837–848.e2 (2018).

- 1167 144. Bussu, G., Jones, E. J. H., Charman, T., Johnson, M. H. & Buitelaar, J. K. Latent trajectories of
 1168 adaptive behaviour in infants at high and low familial risk for autism spectrum disorder. *Mol.*
 1169 *Autism* **10**, (2019).
- 1170 145. Zerbi, V. *et al.* Dysfunctional Autism Risk Genes Cause Circuit-Specific Connectivity Deficits With
 1171 Distinct Developmental Trajectories. *Cereb. Cortex* **28**, 2495–2506 (2018).
- 1172 146. Fein, D. *et al.* Optimal outcome in individuals with a history of autism. *J. Child Psychol. Psychiatry*
 1173 **54**, 195–205 (2013).
- 1174 147. Anderson, D. K., Liang, J. W. & Lord, C. Predicting young adult outcome among more and less
 1175 cognitively able individuals with autism spectrum disorders. *J. Child Psychol. Psychiatry* **55**, 485–
 1176 494 (2013).
- 1177 148. Chlebowski, C., Robins, D. L., Barton, M. L. & Fein, D. Large-Scale Use of the Modified Checklist for
 1178 Autism in Low-Risk Toddlers. *Pediatrics* **131**, e1121–e1127 (2013).
- 1179 149. Stenberg, N. *et al.* Identifying Children with Autism Spectrum Disorder at 18 Months in a General
 1180 Population Sample. *Paediatr. Perinat. Epidemiol.* **28**, 255–262 (2014).
- 1181 150. Pierce, K., Courchesne, E. & Bacon, E. To Screen or Not to Screen Universally for Autism is not the
 1182 Question: Why the Task Force Got It Wrong. *J. Pediatr.* **176**, 182–194 (2016).
- 1183 151. Siu, A. L. *et al.* Screening for Autism Spectrum Disorder in Young Children: US Preventive Services
 1184 Task Force Recommendation Statement. *JAMA* **315**, 691 (2016).
- 1185 152. Øien, R. A. *et al.* Clinical Features of Children With Autism Who Passed 18-Month Screening.
 1186 *Pediatrics* **141**, e20173596 (2018).
- 1187 153. Sánchez-García, A. B., Galindo-Villardón, P., Nieto-Librero, A. B., Martín-Rodero, H. & Robins, D. L.
 1188 Toddler Screening for Autism Spectrum Disorder: A Meta-Analysis of Diagnostic Accuracy. *J. Autism*
 1189 *Dev. Disord.* **49**, 1837–1852 (2019).

- 1190 154. Marlow, M., Servili, C. & Tomlinson, M. A review of screening tools for the identification of autism
1191 spectrum disorders and developmental delay in infants and young children: recommendations for
1192 use in low- and middle-income countries. *Autism Res.* **12**, 176–199 (2019).
- 1193 155. Raza, S. *et al.* Brief Report: Evaluation of the Short Quantitative Checklist for Autism in Toddlers (Q-
1194 CHAT-10) as a Brief Screen for Autism Spectrum Disorder in a High-Risk Sibling Cohort. *J. Autism*
1195 *Dev. Disord.* **49**, 2210–2218 (2019).
- 1196 156. Charman, T. *et al.* Testing two screening instruments for autism spectrum disorder in UK
1197 community child health services. *Dev. Med. Child Neurol.* **58**, 369–375 (2015).
- 1198 157. Brett, D., Warnell, F., McConachie, H. & Parr, J. R. Factors Affecting Age at ASD Diagnosis in UK: No
1199 Evidence that Diagnosis Age has Decreased Between 2004 and 2014. *J. Autism Dev. Disord.* **46**,
1200 1974–1984 (2016).
- 1201 158. Zuckerman, K. E., Lindly, O. J. & Sinche, B. K. Parental Concerns, Provider Response, and Timeliness
1202 of Autism Spectrum Disorder Diagnosis. *J. Pediatr.* **166**, 1431-1439.e1 (2015).
- 1203 159. Boterberg, S., Charman, T., Marschik, P. B., Bölte, S. & Roeyers, H. Regression in autism spectrum
1204 disorder: A critical overview of retrospective findings and recommendations for future research.
1205 *Neurosci. Biobehav. Rev.* **102**, 24–55 (2019).
- 1206 160. Pearson, N., Charman, T., Happé, F., Bolton, P. F. & McEwen, F. S. Regression in autism spectrum
1207 disorder: Reconciling findings from retrospective and prospective research. *Autism Res.* **11**, 1602–
1208 1620 (2018).
- 1209 161. Ozonoff, S. & Iosif, A.-M. Changing conceptualizations of regression: What prospective studies
1210 reveal about the onset of autism spectrum disorder. *Neurosci. Biobehav. Rev.* **100**, 296–304 (2019).

1211 **Despite its potential importance as biological marker and/or subgroup of ASD, developmental**
1212 **regression has remained very poorly understood. This paper outlines recent data and**
1213 **reconceptualization about patterns of onset (and loss) that chimes with a more contemporaneous**
1214 **understanding of ASD as a heterogeneous condition in terms of its manifestation both within and**
1215 **across individuals.**

- 1216 162. Brugha, T. S. *et al.* Validating two survey methods for identifying cases of autism spectrum disorder
1217 among adults in the community. *Psychol. Med.* **42**, 647–656 (2011).
- 1218 163. Brugha, T. S. The Psychiatry of Adult Autism and Asperger Syndrome. *Oxf. Med. Online* (2018)
1219 doi:10.1093/med/9780198796343.001.0001.
- 1220 164. Epstein, J., Johnson, D. E. & Conners, C. K. Conners' Adult ADHD Diagnostic Interview for DSM-IV™.
1221 (2012) doi:10.1037/t04960-000.
- 1222 165. Lai, M.-C. *et al.* Prevalence of co-occurring mental health diagnoses in the autism population: a
1223 systematic review and meta-analysis. *Lancet Psychiatry* **6**, 819–829 (2019).
- 1224 166. Havdahl, A. & Bishop, S. Heterogeneity in prevalence of co-occurring psychiatric conditions in
1225 autism. *Lancet Psychiatry* **6**, 794–795 (2019).
- 1226 167. Croen, L. A. *et al.* The health status of adults on the autism spectrum. *Autism* **19**, 814–823 (2015).
- 1227 168. Mannion, A., Leader, G. & Healy, O. An investigation of comorbid psychological disorders, sleep
1228 problems, gastrointestinal symptoms and epilepsy in children and adolescents with Autism
1229 Spectrum Disorder. *Res. Autism Spectr. Disord.* **7**, 35–42 (2013).
- 1230 169. Soke, G. N., Maenner, M. J., Christensen, D., Kurzius-Spencer, M. & Schieve, L. A. Prevalence of Co-
1231 occurring Medical and Behavioral Conditions/Symptoms Among 4- and 8-Year-Old Children with
1232 Autism Spectrum Disorder in Selected Areas of the United States in 2010. *J. Autism Dev. Disord.* **48**,
1233 2663–2676 (2018).
- 1234 170. Chandler, S. *et al.* Emotional and behavioural problems in young children with autism spectrum
1235 disorder. *Dev. Med. Child Neurol.* **58**, 202–208 (2016).
- 1236 171. Pezzimenti, F., Han, G. T., Vasa, R. A. & Gotham, K. Depression in Youth with Autism Spectrum
1237 Disorder. *Child Adolesc. Psychiatr. Clin. N. Am.* **28**, 397–409 (2019).
- 1238 172. Hwang, Y. I. (Jane), Srasuebkul, P., Foley, K., Arnold, S. & Trollor, J. N. Mortality and cause of death
1239 of Australians on the autism spectrum. *Autism Res.* **12**, 806–815 (2019).

- 1240 173. Hirvikoski, T. *et al.* Premature mortality in autism spectrum disorder. *Br. J. Psychiatry* **208**, 232–238
 1241 (2016).
- 1242 174. Havdahl, K. A. *et al.* Multidimensional Influences on Autism Symptom Measures: Implications for
 1243 Use in Etiological Research. *J. Am. Acad. Child Adolesc. Psychiatry* **55**, 1054–1063.e3 (2016).
- 1244 175. Nicolaidis, C. *et al.* Comparison of healthcare experiences in autistic and non-autistic adults: a
 1245 cross-sectional online survey facilitated by an academic-community partnership. *J. Gen. Intern.*
 1246 *Med.* **28**, 761–769 (2013).
- 1247 176. Schreibman, L. *et al.* Naturalistic Developmental Behavioral Interventions: Empirically Validated
 1248 Treatments for Autism Spectrum Disorder. *J. Autism Dev. Disord.* **45**, 2411–2428 (2015).
- 1249 177. Tomlinson, M. *et al.* Setting global research priorities for developmental disabilities, including
 1250 intellectual disabilities and autism: Setting research priorities for developmental disabilities. *J.*
 1251 *Intellect. Disabil. Res.* **58**, 1121–1130 (2014).
- 1252 178. Rahman, A. *et al.* Effectiveness of the parent-mediated intervention for children with autism
 1253 spectrum disorder in south Asia in India and Pakistan (PASS): a randomised controlled trial. *Lancet*
 1254 *Psychiatry* **3**, 128–136 (2016).
- 1255 179. Lovaas, O. I. Behavioral treatment and normal educational and intellectual functioning in young
 1256 autistic children. *J. Consult. Clin. Psychol.* **55**, 3–9 (1987).
- 1257 180. Nevill, R. E., Lecavalier, L. & Stratis, E. A. Meta-analysis of parent-mediated interventions for young
 1258 children with autism spectrum disorder. *Autism Int. J. Res. Pract.* **22**, 84–98 (2018).
- 1259 181. Kasari, C. *et al.* Randomized controlled trial of parental responsiveness intervention for toddlers at
 1260 high risk for autism. *Infant Behav. Dev.* **37**, 711–721 (2014).
- 1261 182. Shire, S. Y. *et al.* Hybrid implementation model of community-partnered early intervention for
 1262 toddlers with autism: a randomized trial. *J. Child Psychol. Psychiatry* **58**, 612–622 (2016).

- 1263 183. Siller, M., Hutman, T. & Sigman, M. A Parent-Mediated Intervention to Increase Responsive
 1264 Parental Behaviors and Child Communication in Children with ASD: A Randomized Clinical Trial. *J.*
 1265 *Autism Dev. Disord.* **43**, 540–555 (2013).
- 1266 184. Rogers, S. J. *et al.* Effects of a Brief Early Start Denver Model (ESDM)–Based Parent Intervention on
 1267 Toddlers at Risk for Autism Spectrum Disorders: A Randomized Controlled Trial. *J. Am. Acad. Child*
 1268 *Adolesc. Psychiatry* **51**, 1052–1065 (2012).
- 1269 185. Green, J. *et al.* Parent-mediated communication-focused treatment in children with autism (PACT):
 1270 a randomised controlled trial. *The Lancet* **375**, 2152–2160 (2010).
- 1271 186. Pickles, A. *et al.* Parent-mediated social communication therapy for young children with autism
 1272 (PACT): long-term follow-up of a randomised controlled trial. *The Lancet* **388**, 2501–2509 (2016).
- 1273 187. Dawson, G. *et al.* Randomized, Controlled Trial of an Intervention for Toddlers With Autism: The
 1274 Early Start Denver Model. *Pediatrics* **125**, e17–e23 (2009).
- 1275 188. Charman, T. Editorial: Trials and Tribulations in Early Autism Intervention Research. *J. Am. Acad.*
 1276 *Child Adolesc. Psychiatry* (2019) doi:10.1016/j.jaac.2019.03.004.
- 1277 189. Rogers, S. J. *et al.* A Multisite Randomized Controlled Two-Phase Trial of the Early Start Denver
 1278 Model Compared to Treatment as Usual. *J. Am. Acad. Child Adolesc. Psychiatry* **58**, 853–865
 1279 (2019).
- 1280 190. Dawson, G. *et al.* Early Behavioral Intervention Is Associated With Normalized Brain Activity in
 1281 Young Children With Autism. *J. Am. Acad. Child Adolesc. Psychiatry* **51**, 1150–1159 (2012).
- 1282 191. Myers, S. M., Johnson, C. P. & the Council on Children With Disabilities. Management of Children
 1283 With Autism Spectrum Disorders. *Pediatrics* **120**, 1162–1182 (2007).
- 1284 192. Laugeson, E. A., Frankel, F., Gantman, A., Dillon, A. R. & Mogil, C. Evidence-Based Social Skills
 1285 Training for Adolescents with Autism Spectrum Disorders: The UCLA PEERS Program. *J. Autism Dev.*
 1286 *Disord.* **42**, 1025–1036 (2011).

- 1287 193. Reichow, B., Servili, C., Yasamy, M. T., Barbui, C. & Saxena, S. Non-Specialist Psychosocial
 1288 Interventions for Children and Adolescents with Intellectual Disability or Lower-Functioning Autism
 1289 Spectrum Disorders: A Systematic Review. *PLoS Med.* **10**, e1001572 (2013).
- 1290 194. Brignell, A. *et al.* Communication interventions for autism spectrum disorder in minimally verbal
 1291 children. *Cochrane Database Syst. Rev.* (2018) doi:10.1002/14651858.CD012324.pub2.
- 1292 195. Tarver, J. *et al.* Child and parent outcomes following parent interventions for child emotional and
 1293 behavioral problems in autism spectrum disorders: A systematic review and meta-analysis. *Autism*
 1294 **23**, 1630–1644 (2019).
- 1295 196. Keefer, A. *et al.* Exploring Relationships Between Negative Cognitions and Anxiety Symptoms in
 1296 Youth With Autism Spectrum Disorder. *Behav. Ther.* **49**, 730–740 (2018).
- 1297 197. Bearss, K. *et al.* Effect of Parent Training vs Parent Education on Behavioral Problems in Children
 1298 With Autism Spectrum Disorder. *JAMA* **313**, 1524 (2015).
- 1299 198. Da Paz, N. S. & Wallander, J. L. Interventions that target improvements in mental health for
 1300 parents of children with autism spectrum disorders: A narrative review. *Clin. Psychol. Rev.* **51**, 1–14
 1301 (2017).
- 1302 199. Kasari, C. *et al.* Children with autism spectrum disorder and social skills groups at school: a
 1303 randomized trial comparing intervention approach and peer composition. *J. Child Psychol.*
 1304 *Psychiatry* **57**, 171–179 (2016).
- 1305 200. Marshall, D. *et al.* Social Stories in mainstream schools for children with autism spectrum disorder:
 1306 a feasibility randomised controlled trial. *BMJ Open* **6**, e011748 (2016).
- 1307 201. Taylor, J. L. *et al.* A Systematic Review of Vocational Interventions for Young Adults With Autism
 1308 Spectrum Disorders. *Pediatrics* **130**, 531–538 (2012).

- 1309 202. Pallathra, A. A., Cordero, L., Wong, K. & Brodtkin, E. S. Psychosocial Interventions Targeting Social
 1310 Functioning in Adults on the Autism Spectrum: a Literature Review. *Curr. Psychiatry Rep.* **21**,
 1311 (2019).
- 1312 203. White, S. W. *et al.* Psychosocial Treatments Targeting Anxiety and Depression in Adolescents and
 1313 Adults on the Autism Spectrum: Review of the Latest Research and Recommended Future
 1314 Directions. *Curr. Psychiatry Rep.* **20**, (2018).
- 1315 204. Shattuck, P. T., Wagner, M., Narendorf, S., Sterzing, P. & Hensley, M. Post–High School Service Use
 1316 Among Young Adults With an Autism Spectrum Disorder. *Arch. Pediatr. Adolesc. Med.* **165**, (2011).
- 1317 205. Wehman, P. *et al.* Effects of an employer-based intervention on employment outcomes for youth
 1318 with significant support needs due to autism. *Autism* **21**, 276–290 (2016).
- 1319 206. McCracken, J. T. *et al.* Risperidone in Children with Autism and Serious Behavioral Problems. *N.*
 1320 *Engl. J. Med.* **347**, 314–321 (2002).
- 1321 207. Owen, R. *et al.* Aripiprazole in the Treatment of Irritability in Children and Adolescents With
 1322 Autistic Disorder. *Pediatrics* **124**, 1533–1540 (2009).
- 1323 208. McPheeters, M. L. *et al.* A Systematic Review of Medical Treatments for Children With Autism
 1324 Spectrum Disorders. *Pediatrics* **127**, e1312–e1321 (2011).
- 1325 209. Anagnostou, E. *et al.* Metformin for Treatment of Overweight Induced by Atypical Antipsychotic
 1326 Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial. *JAMA*
 1327 *Psychiatry* **73**, 928 (2016).
- 1328 210. Randomized, Controlled, Crossover Trial of Methylphenidate in Pervasive Developmental Disorders
 1329 With Hyperactivity. *Arch. Gen. Psychiatry* **62**, 1266 (2005).
- 1330 211. Handen, B. L. *et al.* Atomoxetine, Parent Training, and Their Combination in Children With Autism
 1331 Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder. *J. Am. Acad. Child Adolesc.*
 1332 *Psychiatry* **54**, 905–915 (2015).

- 1333 212. Scahill, L. *et al.* Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum
1334 Disorder. *Am. J. Psychiatry* **172**, 1197–1206 (2015).
- 1335 213. Hollander, E. *et al.* A Double-Blind Placebo-Controlled Trial of Fluoxetine for Repetitive Behaviors
1336 and Global Severity in Adult Autism Spectrum Disorders. *Am. J. Psychiatry* **169**, 292–299 (2012).
- 1337 214. King, B. H. *et al.* Lack of Efficacy of Citalopram in Children With Autism Spectrum Disorders and
1338 High Levels of Repetitive Behavior: Citalopram Ineffective in Children With Autism. *Arch. Gen.*
1339 *Psychiatry* **66**, 583 (2009).
- 1340 215. Anagnostou, E. *et al.* Intranasal oxytocin in the treatment of autism spectrum disorders: A review
1341 of literature and early safety and efficacy data in youth. *Brain Res.* **1580**, 188–198 (2014).
- 1342 216. Guastella, A. J. *et al.* The effects of a course of intranasal oxytocin on social behaviors in youth
1343 diagnosed with autism spectrum disorders: a randomized controlled trial. *J. Child Psychol.*
1344 *Psychiatry* **56**, 444–452 (2015).
- 1345 217. Parker, K. J. *et al.* A randomized placebo-controlled pilot trial shows that intranasal vasopressin
1346 improves social deficits in children with autism. *Sci. Transl. Med.* **11**, eaau7356 (2019).
- 1347 218. Bolognani, F. *et al.* A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved
1348 adaptive behaviors in men with autism spectrum disorder. *Sci. Transl. Med.* **11**, eaat7838 (2019).
- 1349 219. Rubenstein, J. L. R. & Merzenich, M. M. Model of autism: increased ratio of excitation/inhibition in
1350 key neural systems. *Genes Brain Behav.* **2**, 255–267 (2003).
- 1351 220. Veenstra-VanderWeele, J. *et al.* Arbaclofen in Children and Adolescents with Autism Spectrum
1352 Disorder: A Randomized, Controlled, Phase 2 Trial. *Neuropsychopharmacology* **42**, 1390–1398
1353 (2016).
- 1354 221. Berry-Kravis, E. *et al.* Mavoglurant in fragile X syndrome: Results of two randomized, double-blind,
1355 placebo-controlled trials. *Sci. Transl. Med.* **8**, 321ra5–321ra5 (2016).

- 1356 222. Krueger, D. A. *et al.* Everolimus for treatment of tuberous sclerosis complex-associated
 1357 neuropsychiatric disorders. *Ann. Clin. Transl. Neurol.* **4**, 877–887 (2017).
- 1358 223. Georgiades, S. & Kasari, C. Reframing Optimal Outcomes in Autism. *JAMA Pediatr.* **172**, 716 (2018).
- 1359 224. Bishop-Fitzpatrick, L. *et al.* Characterizing Objective Quality of Life and Normative Outcomes in
 1360 Adults with Autism Spectrum Disorder: An Exploratory Latent Class Analysis. *J. Autism Dev. Disord.*
 1361 **46**, 2707–2719 (2016).
- 1362 225. THE WHOQOL GROUP. Development of the World Health Organization WHOQOL-BREF Quality of
 1363 Life Assessment. *Psychol. Med.* **28**, 551–558 (1998).
- 1364 226. Gotham, K. *et al.* Characterizing the daily life, needs, and priorities of adults with autism spectrum
 1365 disorder from Interactive Autism Network data. *Autism* **19**, 794–804 (2015).
- 1366 227. Taylor, J. L. & Seltzer, M. M. Employment and Post-Secondary Educational Activities for Young
 1367 Adults with Autism Spectrum Disorders During the Transition to Adulthood. *J. Autism Dev. Disord.*
 1368 **41**, 566–574 (2010).
- 1369 228. Orsmond, G. I., Shattuck, P. T., Cooper, B. P., Sterzing, P. R. & Anderson, K. A. Social Participation
 1370 Among Young Adults with an Autism Spectrum Disorder. *J. Autism Dev. Disord.* **43**, 2710–2719
 1371 (2013).
- 1372 229. Henninger, N. A. & Taylor, J. L. Outcomes in adults with autism spectrum disorders: a historical
 1373 perspective. *Autism* **17**, 103–116 (2012).
- 1374 230. Howlin, P. & Moss, P. Adults with Autism Spectrum Disorders. *Can. J. Psychiatry* **57**, 275–283
 1375 (2012).
- 1376 231. Farley, M. A. *et al.* Twenty-year outcome for individuals with autism and average or near-average
 1377 cognitive abilities. *Autism Res.* **2**, 109–118 (2009).
- 1378 232. Taylor, J. L., Henninger, N. A. & Mailick, M. R. Longitudinal patterns of employment and
 1379 postsecondary education for adults with autism and average-range IQ. *Autism* **19**, 785–793 (2015).

- 1380 233. Lai, M.-C. *et al.* Quantifying and exploring camouflaging in men and women with autism. *Autism*
 1381 **21**, 690–702 (2016).
- 1382 234. van Heijst, B. F. & Geurts, H. M. Quality of life in autism across the lifespan: A meta-analysis.
 1383 *Autism* **19**, 158–167 (2014).
- 1384 235. Moss, P., Mandy, W. & Howlin, P. Child and Adult Factors Related to Quality of Life in Adults with
 1385 Autism. *J. Autism Dev. Disord.* **47**, 1830–1837 (2017).
- 1386 236. Bishop-Fitzpatrick, L., Mazefsky, C. A. & Eack, S. M. The combined impact of social support and
 1387 perceived stress on quality of life in adults with autism spectrum disorder and without intellectual
 1388 disability. *Autism* **22**, 703–711 (2017).
- 1389 237. Kamio, Y., Inada, N. & Koyama, T. A nationwide survey on quality of life and associated factors of
 1390 adults with high-functioning autism spectrum disorders. *Autism* **17**, 15–26 (2012).
- 1391 238. Mason, D. *et al.* Predictors of quality of life for autistic adults. *Autism Res.* **11**, 1138–1147 (2018).
- 1392 239. Autistica. *Your questions shaping future autism research.*
 1393 [https://www.autistica.org.uk/downloads/files/Autism-Top-10-Your-Priorities-for-Autism-](https://www.autistica.org.uk/downloads/files/Autism-Top-10-Your-Priorities-for-Autism-Research.pdf)
 1394 [Research.pdf](https://www.autistica.org.uk/downloads/files/Autism-Top-10-Your-Priorities-for-Autism-Research.pdf). (2016).
- 1395 240. Ontario Brain Institute. *Ontario Brain Institute. Community Priorities for Research on*
 1396 *Neurodevelopmental Disorders. (2018). Available at: [http://braininstitute.ca/img/JLA-NDD-Final-](http://braininstitute.ca/img/JLA-NDD-Final-Report.pdf)*
 1397 *Report.pdf. <http://braininstitute.ca/img/JLA-NDD-Final-Report.pdf>. (2018).*
- 1398 241. den Houting, J. Neurodiversity: An insider’s perspective. *Autism* **23**, 271–273 (2018).
- 1399 242. Szatmari, P. Risk and resilience in autism spectrum disorder: a missed translational opportunity?
 1400 *Dev. Med. Child Neurol.* **60**, 225–229 (2017).
- 1401 243. Markowitz, L. A. *et al.* Development and psychometric evaluation of a psychosocial quality-of-life
 1402 questionnaire for individuals with autism and related developmental disorders. *Autism* **20**, 832–
 1403 844 (2016).

- 1404 244. Ryan, S. & Cole, K. R. From Advocate to Activist? Mapping the Experiences of Mothers of Children
1405 on the Autism Spectrum. *J. Appl. Res. Intellect. Disabil.* **22**, 43–53 (2009).
- 1406 245. McCann, D., Bull, R. & Winzenberg, T. The daily patterns of time use for parents of children with
1407 complex needs. *J. Child Health Care* **16**, 26–52 (2012).
- 1408 246. Karst, J. S. & Van Hecke, A. V. Parent and Family Impact of Autism Spectrum Disorders: A Review
1409 and Proposed Model for Intervention Evaluation. *Clin. Child Fam. Psychol. Rev.* **15**, 247–277 (2012).
- 1410 247. Lounds, J., Seltzer, M. M., Greenberg, J. S. & Shattuck, P. T. Transition and Change in Adolescents
1411 and Young Adults With Autism: Longitudinal Effects on Maternal Well-Being. *Am. J. Ment. Retard.*
1412 **112**, 401 (2007).
- 1413 248. Burke, M. & Heller, T. Individual, parent and social-environmental correlates of caregiving
1414 experiences among parents of adults with autism spectrum disorder. *J. Intellect. Disabil. Res.* **60**,
1415 401–411 (2016).
- 1416 249. Kim, S. H., Bal, V. H. & Lord, C. Longitudinal follow-up of academic achievement in children with
1417 autism from age 2 to 18. *J. Child Psychol. Psychiatry* **59**, 258–267 (2017).
- 1418 250. Lord, C., Bishop, S. & Anderson, D. Developmental trajectories as autism phenotypes. *Am. J. Med.*
1419 *Genet. C Semin. Med. Genet.* **169**, 198–208 (2015).
- 1420 251. Amaral, D. G. *et al.* Gaps in Current Autism Research: The Thoughts of the *Autism Research*
1421 Editorial Board and Associate Editors. *Autism Res.* **12**, 700–714 (2019).
- 1422 252. Kahn, R. S. *et al.* Schizophrenia. *Nat. Rev. Dis. Primer* **1**, (2015).
- 1423 253. Lord, C., Elsabbagh, M., Baird, G. & Veenstra-Vanderweele, J. Autism spectrum disorder. *The*
1424 *Lancet* **392**, 508–520 (2018).
- 1425 254. Duncan, A. W. & Bishop, S. L. Understanding the gap between cognitive abilities and daily living
1426 skills in adolescents with autism spectrum disorders with average intelligence. *Autism* **19**, 64–72
1427 (2013).

- 1428 255. Sadowsky, J. John Donovan, Carrie Zucker. In a different key: The story of autism. *J. Hist. Behav. Sci.*
 1429 **54**, 66–67 (2018).
- 1430 **This paper presents a different, broad overview of the changes in perspective about autism and ASD**
 1431 **over the years.**
- 1432 256. Rutter, M., Greenfeld, D. & Lockyer, L. A Five to Fifteen Year Follow-Up Study of Infantile Psychosis.
 1433 *Br. J. Psychiatry* **113**, 1183–1199 (1967).
- 1434 257. B. Hermelin & N. O'Connor. *Psychological Experiments With Autistic Children*. (Pergamon Press,
 1435 1970).
- 1436 258. Rimland, B. *Infantile Autism: the Syndrome and Its Implications for a Neural Theory of Behaviour*.
 1437 (Meredith Publishing Compan, 1964).
- 1438 259. Frith, U. Studies in pattern detection in normal and autistic children: I. Immediate recall of auditory
 1439 sequences. *J. Abnorm. Psychol.* **76**, 413–420 (1970).
- 1440 260. Folstein, S. & Rutter, M. A Twin Study of Individuals with Infantile Autism. *Autism* 219–241 (1978)
 1441 doi:10.1007/978-1-4684-0787-7_15.
- 1442 261. Mundy, P., Sigman, M. & Kasari, C. A longitudinal study of joint attention and language
 1443 development in autistic children. *J. Autism Dev. Disord.* **20**, 115–128 (1990).
- 1444 262. Pickles, A, McCauley, J.B., Pepa, L., Huerta, M. & Lord, C. The adult outcome of children referred
 1445 for autism: Typology and prediction from childhood. *J. Cons. and Clin. Psyc.* (2019).
- 1446 263. Schopler, E. & Reichler, R. J. Parents as cotherapists in the treatment of psychotic children. *J.*
 1447 *Autism Child. Schizophr.* **1**, 87–102 (1971).
- 1448 264. Sinclair, J. *Don't mourn for us*. http://www.autreat.com/dont_mourn.html. (1993).
- 1449 265. Wing, L. & Gould, J. Severe impairments of social interaction and associated abnormalities in
 1450 children: Epidemiology and classification. *J. Autism Dev. Disord.* **9**, 11–29 (1979).

- 1451 266. Chawner, S. *et al.* A genetic first approach to dissecting the heterogeneity of autism: phenotypic
 1452 comparison of autism risk copy number variants. *Eur. Neuropsychopharmacol.* **29**, S783–S784
 1453 (2019).
- 1454 267. Modabbernia, A., Mollon, J., Boffetta, P. & Reichenberg, A. Impaired Gas Exchange at Birth and
 1455 Risk of Intellectual Disability and Autism: A Meta-analysis. *J. Autism Dev. Disord.* **46**, 1847–1859
 1456 (2016).
- 1457 268. Christensen, J. *et al.* Prenatal Valproate Exposure and Risk of Autism Spectrum Disorders and
 1458 Childhood Autism. *JAMA* **309**, 1696 (2013).
- 1459 269. Xie, F., Peltier, M. & Getahun, D. Is the Risk of Autism in Younger Siblings of Affected Children
 1460 Moderated by Sex, Race/Ethnicity, or Gestational Age? *J. Dev. Behav. Pediatr.* **37**, 603–609 (2016).
- 1461 270. Guy, A. *et al.* Infants Born Late/Moderately Preterm Are at Increased Risk for a Positive Autism
 1462 Screen at 2 Years of Age. *J. Pediatr.* **166**, 269-275.e3 (2015).
- 1463 271. Schendel, D. & Bhasin, T. K. Birth Weight and Gestational Age Characteristics of Children With
 1464 Autism, Including a Comparison With Other Developmental Disabilities. *Pediatrics* **121**, 1155–1164
 1465 (2008).
- 1466 272. Windham, G. C. *et al.* Maternal Pre-pregnancy Body Mass Index and Gestational Weight Gain in
 1467 Relation to Autism Spectrum Disorder and other Developmental Disorders in Offspring. *Autism*
 1468 *Res.* **12**, 316–327 (2018).
- 1469 273. Schmidt, R. J. *et al.* Maternal periconceptional folic acid intake and risk of autism spectrum
 1470 disorders and developmental delay in the CHARGE (Childhood Autism Risks from Genetics and
 1471 Environment) case-control study. *Am. J. Clin. Nutr.* **96**, 80–89 (2012).
- 1472 274. Conde-Agudelo, A., Rosas-Bermudez, A. & Norton, M. H. Birth Spacing and Risk of Autism and
 1473 Other Neurodevelopmental Disabilities: A Systematic Review. *Pediatrics* **137**, e20153482–
 1474 e20153482 (2016).

- 1475 275. Lyall, K. *et al.* The Changing Epidemiology of Autism Spectrum Disorders. *Annu. Rev. Public Health*
 1476 **38**, 81–102 (2017).
- 1477 276. Cheslack-Postava, K., Liu, K. & Bearman, P. S. Closely Spaced Pregnancies Are Associated With
 1478 Increased Odds of Autism in California Sibling Births. *Pediatrics* **127**, 246–253 (2011).
- 1479 277. Conti, E., Mazzotti, S., Calderoni, S., Saviozzi, I. & Guzzetta, A. Are children born after assisted
 1480 reproductive technology at increased risk of autism spectrum disorders? A systematic review.
 1481 *Hum. Reprod.* **28**, 3316–3327 (2013).
- 1482 278. Lehti, V. *et al.* Autism spectrum disorders in IVF children: a national case-control study in Finland.
 1483 *Hum. Reprod.* **28**, 812–818 (2013).
- 1484 279. Rossignol, D. A., Genuis, S. J. & Frye, R. E. Environmental toxicants and autism spectrum disorders:
 1485 a systematic review. *Transl. Psychiatry* **4**, e360–e360 (2014).
- 1486 280. Curran, E. A. *et al.* Research Review: Birth by caesarean section and development of autism
 1487 spectrum disorder and attention-deficit/hyperactivity disorder: a systematic review and meta-
 1488 analysis. *J. Child Psychol. Psychiatry* **56**, 500–508 (2014).
- 1489 281. Chandler, S., Howlin, P., Simonoff, E., Kennedy, J. & Baird, G. Comparison of parental estimate of
 1490 developmental age with measured IQ in children with neurodevelopmental disorders. *Child Care*
 1491 *Health Dev.* **42**, 486–493 (2016).
- 1492 282. Charman, T. *et al.* IQ in children with autism spectrum disorders: data from the Special Needs and
 1493 Autism Project (SNAP). *Psychol. Med.* **41**, 619–627 (2010).
- 1494 283. Sparrow, S. S., Cicchetti, D. & Balla, D. A. Vineland Adaptive Behavior Scales, Second Edition. (2005)
 1495 doi:10.1037/t15164-000.
- 1496 284. Jones, R. M., Pickles, A. & Lord, C. Evaluating the quality of peer interactions in children and
 1497 adolescents with autism with the Penn Interactive Peer Play Scale (PIPPS). *Mol. Autism* **8**, (2017).

285. Patel, V. *et al.* Addressing the burden of mental, neurological, and substance use disorders: key messages from Disease Control Priorities, 3rd edition. *The Lancet* **387**, 1672–1685 (2016).
286. Franz, L., Chambers, N., von Isenburg, M. & de Vries, P. J. Autism spectrum disorder in sub-saharan africa: A comprehensive scoping review: Autism spectrum disorder in sub-Saharan Africa. *Autism Res.* **10**, 723–749 (2017).
287. WHO. *Training parents to transform children's lives.*
https://www.who.int/mental_health/maternal-child/PST/en/.
288. Naslund, J. A. *et al.* Digital Innovations for Global Mental Health: Opportunities for Data Science, Task Sharing, and Early Intervention. *Curr. Treat. Options Psychiatry* (2019) doi:10.1007/s40501-019-00186-8.

Acknowledgements

The authors thank James McCauley, Sandra Gaspar, Katherine Byrne, and Alison Holbrook from UCLA for help with manuscript preparation. Dr. Samul Tromans is thanked for his updated review of the epidemiology literature. We recognize the many investigators who contributed research that we cannot cite due to space limits. C.L. is supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD; R01 HD081199), the National Institute of Mental Health (NIMH; R01MH081873-01A1) and the Simons Foundation. T.S.B. is supported by grants from the Health and Social Care Information Centre, Leeds, and the National Institute for Health Research (NIHR HTA [Grant ref NIHR127337]). T.C. is supported by grants from Innovative Medicines Initiative 2 (No 777394), the Medical Research Council (MRC; grants MR/K021389/1), and the NIHR (grant 13/119/18). J.C. is funded by Autistica. G.D. is supported by the Institut Pasteur. T.F. is supported by the Autism Speaks Foundation. E.J. is supported by grants from the Economic and Social Research Council (ESRC; ES/R009368/1), the Innovative Medicines Initiative 2 (No 777394) and the MRC (MR/K021389/1) the Simons Foundation (609081). R.J. would like to acknowledge the Mortimer D. Sackler Family and the NIMH: R01MH114999. J.L.T. is supported by grants from the FAR fund and the National Institutes of Mental Health (R34 MH104428, R03 MH 112783, R01 MH116058). A.P. is partially supported by Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London and NIHR NF-SI-0617-10120. M.S. is supported by the National Institute of Health (NIH, MH106934, MH109901, MH110928, MH116487 MH102342, MH111662, MH105575, MH115747), the Overlook International Foundation and the Simons Foundation. J.V. is supported by the National Institutes of Health (NIH; MH016434, MH094604), the Simons Foundation, and the New York State Psychiatric Institute. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

1532 **Author Contributions**

1533 All authors read and edited the full document. Introduction (C.L.), Epidemiology (T.S.B.),
 1534 Mechanisms/pathophysiology (M.W.S., G.D., R.M.J., T.C. and E.J.); Diagnosis, screening and prevention
 1535 (T.C., E.J. and T.S.B.), Management (T.S.B., T.C., E.J., J.L.T. and J.V.), Quality of life (J.L.T., J.C. and T.F.),
 1536 Outlook (C.L. and A.P.); Overview of Primer (C.L.).

1537

1538 **Competing Interests**

1539 C.L. acknowledges the receipt of royalties from Western Psychological Services for the sale of the Autism
 1540 Diagnostic Interview-Revised (ADIR), the Autism Diagnostic Observation Schedule (ADOS) and the Social
 1541 Communication Questionnaire (SCQ). T.S.B. has received royalties from Cambridge University Press and
 1542 Oxford University Press. T.C. has served as a consultant to F. Hoffmann-La Roche Ltd and has received
 1543 royalties from and Guilford Publications and Sage Publications. T.F. has received federal funding
 1544 research support from, acted as a consultant to, received travel support from, and/or received a
 1545 speaker's honorarium from the Brain and Behavior Research Foundation, Bristol-Myers Squibb, the Cole
 1546 Family Research Fund, Ecoeos, Forest Laboratories, Ingalls Foundation, IntegraGen, Kugona LLC,
 1547 National Institutes of Health, Roche Pharma, Shire Development and the Simons Foundation. J.L.T.
 1548 receives compensation from Sage Publishers for editorial work. A.P. receives royalties from Imperial
 1549 College Press, Oxford University Press Western Psychological Services. M.S. serves on the scientific
 1550 advisory boards and has stock or stock options for ARetT Pharmaceuticals and BlackThorn Therapeutics.
 1551 J.V. has consulted or served on an advisory board for Novartis, Roche Pharmaceuticals and SynapDx, has
 1552 received research funding from Forest, Novartis, Roche Pharmaceuticals, Seaside Therapeutics,
 1553 SynapDx, and, and has received an editorial stipend from Springer and Wiley. J.C., E.J., R.J., G.D. declare
 1554 no competing interests.

1555

1556 **Publisher's note**

1557 Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional
 1558 affiliations.

1559

1560 **Peer review information**

1561 Nature Reviews Disease Primers thanks P. Szatmari, S. Spence and the other, anonymous, reviewer(s)
 1562 for their contribution to the peer review of this work.

1563

1564

1565 **Table 1:** Evidence-based medication in autism

Medication	FDA or EMA Indication and age	Effect Size (d)²⁵³	Common Adverse Effects
<i>Typically used for ADHD symptoms</i>			
<i>Methylphenidate</i>	FDA and EMA approval for ADHD (not specific for autism) in those ≥ 6 years of age	d=0.78 (teacher rated)	Sleep disruption and decreased appetite
<i>Atomoxetine</i>	FDA and individual country approval for ADHD (not specific for autism) in those ≥ 6 years of age	d=-0.68–.084	Decreased appetite, nausea and irritability
<i>Guanfacine</i>	FDA and EMA approval for ADHD (not specific for autism) in those 6–17 years of age	d=1.67	Fatigue, sedation and decreased pulse and blood pressure
<i>Typically used to treat agitation and irritability</i>			
<i>Risperidone</i>	FDA approval for irritability associated with autism and EMA approval only for other indications in those 5–17 years of age	d=0.94	Increased appetite, sedation and weight gain
<i>Aripiprazole</i>	FDA approval for irritability associated with autism and EMA approval only for other indications in those 6–17 years of age	d=0.87	Nausea and weight gain

1566 ADHD, attention-deficit/hyperactivity disorder; EMA, European Medicines Agency.

1567

1568 **Table 2:** Factors that affect QOL.

Type of QOL	Factor	Description
Objective QOL	Early language	Follow-up studies of adults with autism who were diagnosed as children have examined the amount of spoken language during early childhood. Individuals with autism who had fluent speech are more likely to have higher levels of objective QOL life in adulthood than those with phrased speech or those with no speech or who spoke in single words.
	Indicators of intelligence	Studies examining IQ scores using standardized IQ tests administered both in early childhood and adulthood find that individuals with autism and higher IQ scores have higher levels of objective QOL than those with lower IQ scores. Other, less-standardized measures of intelligence (such as those used in large cohort studies) have similar findings.
	Adaptive behaviour	Higher levels of adaptive behaviour – and particularly more activities of daily living – are associated with better objective QOL in people with autism. Adaptive behaviour is a challenge for many individuals with autism, who have scores below what would be expected based on IQ ²⁵⁴ . Adaptive behaviour is changeable, making it a promising avenue for interventions to improve objective QOL.
	Autism symptom severity	Individuals with more severe autism symptoms tend to have lower objective QOL in adulthood.
	Challenging behaviours	Higher levels of challenging behaviours in people with autism, which can include both internalizing problems and externalizing problems, are related to lower objective QOL.
	Sex or gender	Sex or gender associations with objective QOL have been demonstrated in terms of employment or post-secondary education. Indeed, women with autism obtain employment and post-secondary educational positions at the same rate as men with autism but have a more difficult time maintaining those positions over time.
Subjective QOL	Perceived stress	Many adults with autism perceive high levels of stress in their own lives. These perceptions are related to lower subjective QOL.
	Supports	Several different types of supports have been related to subjective QOL, including formal services, support from family members (most often parents) and more general social support from others.

1569 QOL, quality of life.

1570

1571

1572

Figure 1. Theories and findings regarding autism mechanisms, outcomes and heterogeneity.

Original descriptions of the cardinal features of autism were attributed to a range of causes including being raised by wolves (the Wild Boy of Aveyron), inborn limitations in affective contact and unfeeling parenting (such as ‘refrigerator mothers’) and holy people (such as fools for Christ))²⁵⁵. Conceptualizations of autism as a common highly heritable neurodevelopmental disorder with underlying cognitive features began with the recognition of differences in brain function and cognition in the 1960s^{256–259} and the first twin study in the 1970s²⁶⁰. Other proposed mechanisms include maturational lags in neurophysiology⁹⁴ and cognitive mechanisms such as joint engagement^{176,261}. With the search for pathways to and sometimes out of autism²⁶² on many levels, conceptualization of positive outcomes has been more recent, but has also varied markedly. In the 1970s, autism societies and collaborative clinical programs focused on community integration and de-institutionalization (such as National Autistic Society (NAS) and National Society for Autistic Children (NSAC))²⁶³. Priorities shifted in the 1980s and 1990s, with still unreplicated claims of ‘recovery’ in children who participated in intensive behavioural interventions¹⁷⁹, new advocacy groups focusing on biomedical discoveries to yield potential biological treatments and even ‘cures’ (such as National Alliance for Autism Research (NAAR) and Cure Autism Now²⁵⁵) and the neurodiversity movement²⁶⁴ which rejected ‘cures’ and called for adaptation of environments to support autistic people, using terminology preferred by self-advocates and community participation. Recognition of the marked heterogeneity within autism began in the 1970’s with the triad of impairments in language, play and social interaction characterizing many children with intellectual disabilities (ID) or those with classical autism²⁶⁵. The first twin study demonstrated that monozygotic twin pairs, though concordant for difficulties associated with autism, differed in specific characteristics and co-occurring conditions including ID²⁶⁰. More recently, phenotypic heterogeneity has been the rule in most, though not all, gene-first phenotypic studies²⁶⁶. Thus, developmental aspects of differences in strengths, difficulties and trajectories, as well as biological factors, require highly personalized conceptualizations of the needs of autistic individuals and their families. ABA, applied behaviour analysis; AGRE, Autism Genetic Resource Exchange; CDC, US Centers for Disease Control and Prevention; DSM, Diagnostic and Statistical Manual of Mental Disorders; EEG, electroencephalography; GRASP, Global and Regional Asperger Syndrome Partnership ;IDEA, Individuals with Disabilities Education Act; MCEP, the gene associated with Rett Syndrome; PACT, Preschool Autism Communication Trial; PDD, pervasive developmental disorder; SNAP, Special Needs and Autism Project; SPARK, Simons Foundation Powering Autism Research for Knowledge, TEACCH, Treatment and Education of Autistic and Communication related handicapped Children.

Figure 2. Environmental risk factors for autism.

Data from studies aiming to identify risk factors for autism can be broadly split into three categories, those with evidence supporting an association (panel a), those with inconclusive evidence (panel b) and importantly, those with no supporting evidence (panel c). Bars represent ranges. *Represents recurrence risk. Figure adapted from¹⁸ with added findings from select reviews and empirical papers: neonatal hypoxia estimate²⁶⁷, childhood vaccines²⁰, valporate use during pregnancy²⁶⁸, parent age estimates²⁶⁹, preterm birth estimate^{270,271}, maternal obesity estimate²⁷², folic acid intake estimate²⁷³, siblings estimate^{274,275}, interpregnancy interval estimate²⁷⁶, assisted reproductive technologies estimate^{277,278}, pesticide and air pollution estimate²⁷⁹, caesarian section estimate²⁸⁰.

1615

1616 **Figure 3.** Encoded proteins associated with autism risk.

1617 Simplified schematic of the major cellular components of a neural circuit in the cerebral cortex, with a
 1618 focus on pyramid-shaped glutamatergic excitatory projection neurons. Proteins encoded by selected
 1619 high-confidence (FDR < 0.1) autism risk genes³⁴ and proteins encoded by selected syndromic autism
 1620 genes have a role in these neurons during development. These proteins have a diverse intracellular
 1621 distribution; those at the synapse, have roles in cell adhesion, scaffolding and signalling. In addition,
 1622 some of these proteins are localized to the nucleus and have been shown, broadly, to mediate
 1623 chromatin modification and transcriptional control. Syndromic autism genes include *FMR1* (encoding
 1624 fragile X mental retardation protein; fragile X syndrome), *UBE3A* (encoding Ubiquitin-protein ligase E3A;
 1625 Angelman syndrome), *TSC1* and *TSC2* (encoding hamartin and tuberin; tuberous sclerosis complex),
 1626 *PTEN* (encoding Phosphatase and tensin homolog) and *MECP2* (encoding methyl-CpG-binding protein 2;
 1627 Rett syndrome). Adapted from ⁴⁸.

1628

1629 **Figure 4.** Longitudinal trajectories of total brain volume, surface area and cortical thickness in autism.

1630 Brain trajectories from 6–24 months of age for total brain volume (TBV, panel a), surface area (SA, panel
 1631 b) and cortical thickness (CT, panel c). Toddlers diagnosed with ASD had significantly greater surface
 1632 area growth from 6-12 months compared to infants who were high risk for ASD but did not receive a
 1633 diagnosis as well as compared to typically developing infants. Differences in surface area growth became
 1634 more pronounced from 12 to 24 months of age for toddlers who received an ASD diagnosis. Corrected
 1635 age refers to the age corrected by length (body size). Adapted from ⁷⁴.

1636

1637 **Figure 5.** Co-occurring disorders.

1638 Primary and secondary disorders and disadvantage can accumulate through development in people with
 1639 autism. These disorders can form additional targets for treatment and policy. Prevalence estimates are
 1640 preliminary, derived from QUEST²⁸¹ SNAP^{282,138} and EDX¹⁴⁷ cohorts, but are limited by the fact that many
 1641 are based on clinical populations or data that are inherently biased (such as US Medicaid data where
 1642 billing for treatment is contingent on having a non-ASD diagnosis) and few well-designed population
 1643 studies exist.

1644 **Figure 6.** Major parental milestones in advocating and supporting their child with autism.

1645 Families of children and adults with autism have many decisions and expectations across the lifespan of
 1646 their children, from seeking initial diagnostic evaluation and intervention to preparing for aging-related
 1647 services. These decisions vary across different cultures, regions and countries and depend on many
 1648 factors, including the resources and services available. However, several decisions are common across
 1649 all regions, including LMICs, such as choices about who will care for their child if the parents are
 1650 temporarily unable, the amount of time parents and other family members can spend with the child
 1651 with autism versus meeting other needs, ways to modify their home environment to ensure the safety
 1652 and independence of the individual with autism and the kinds of behavioural expectations that are most

helpful for their child or adult. Of note, for many families, these choices and responsibilities are lifelong and are relevant, for children, adolescents, adults and elders with autism.

Figure 7. Changes in daily living scores as predicted by IQ scores and autistic symptoms.

Changes in independent daily living skills can be observed in people with autism over time. This sample consists of ~100 young adults with a mean age of 26 years with autism, who were evaluated at 2, 3 and 9 years of age and followed up to 26 years of age. Daily living scores are very diverse, ranging from age-appropriate levels of independence at adulthood (represented by a daily living score of 100, assessed using the Vineland II²⁸³) to very limited skills (represented by a score of <30). Increasing divergence shows where measurement after 2 years of age is additionally predictive, with the line thickness indicating the proportion of early referred children that followed each trajectory. Heterogeneity in intellectual functioning and severity of autism symptoms (social communication and restricted, repetitive, sensory behaviors) can be observed. In addition, improvements and worsening of autistic symptoms and intellectual functioning can occur over time. A, B | Referred children had verbal IQs predominantly <50 (over 3 standard deviations below average) but could show improvement in daily living standard scores from 2 to 3 years of age that were indicative of eventual greater independence in adulthood. Relatively less early change in non-verbal IQ is seen but, like verbal IQ, by adulthood the association with eventual adult daily living skills is strong. C, D | Variation in autism symptom severity in social-communication (CSS refers to The Autism Diagnostic Observation Schedule, Second Edition (ADOS-2) Comparison Scores) showed a stronger association with adult independence than restricted-repetitive behaviours and continued to change over the lifespan following more divergent pathways than intellectual functioning. Data from the EDX cohort compiled from ^{1,147,284}.

1676 **Box 1. ASD as defined in DSM-5^a.**

1677 The Diagnostic and Statistical Manual of Mental disorders, Fifth Edition (DSM-5) criteria for autism
1678 spectrum disorder (ASD) comprise 5 symptom clusters (A-E)

1679 A. Social communication and social interaction.

- 1680 • Must have evidence across multiple contexts of all of the following 3 subdomains currently or by
1681 history
 - 1682 ○ Social reciprocity
 - 1683 ○ Nonverbal communication
 - 1684 ○ Developing, maintaining and understanding relationships

1686 B. Restricted, repetitive behaviours and interests.

- 1687 • Must have evidence of 2 of 4 of the following subdomains currently or by history
 - 1688 ○ Stereotyped, repetitive behaviours
 - 1689 ○ Insistence on sameness
 - 1690 ○ Highly restricted, fixed interests
 - 1691 ○ Hyper- or hyposensitivity or interest in sensory inputs

1693 C. Symptoms must be present in early development but may not be fully manifest until later or may be
1694 masked later in life by learned strategies

1695

1696 D. Symptoms must cause clinically significant impairment in current functioning

1697

1698 E. Not better explained by intellectual disability or global developmental delay

1699

1700 Note: Previously established DSM-IV diagnoses of any pervasive developmental disorder, including
1701 Asperger's disorder should be assumed to be equivalent to DSM-5 ASD. ASD may co-occur with many
1702 other disorders including ADHD, intellectual disability, language delay and genetic syndromes.

1703 ^a Adapted from ref 125.

1704 Box 2. Global challenges in autism research

1705 Recently, there have been calls for more attention to global issues in autism research²⁵¹ (Global
 1706 Research on Developmental Disabilities Collaboration – Lancet Global Health, 2016), including a number
 1707 of related issues with somewhat different potential solutions. For example, broader populations should
 1708 be included in autism research, including individuals from Lower Resource and Middle Income countries
 1709 (LMICs), but also inclusive representation of the ethnic, linguistic and socio-economic diversity of many
 1710 High Resource countries and people whose autism is unrecognised. Moreover, there should be the
 1711 creation of opportunities to carry out research in LMICs²⁸⁵. Open source and shared databanks,
 1712 including autism-specific resources such as the Simons Simplex Collection and Autism Brain Imaging
 1713 Data Exchange (ABIDE), as well as broader collaborations such as PsychENCODE could assist in
 1714 promoting international research. In addition, the science of autism should be disseminated in ways that
 1715 are useful for practice in all countries, but with particular attention to the needs of communities and
 1716 families with fewer resources^{286, 287}. More immediately, searches for scalable methods of identification
 1717 and perhaps intervention with children and adults with autism^{140,288} have begun. However, the need to
 1718 develop scalable global practices highlights how little is known about when we need population-wide
 1719 testing for autism versus broader neurodevelopmental disorders, the minimal intensity and duration of
 1720 effective interventions, behavioural mechanisms behind changes in behaviour and which treatments
 1721 work with which children and adults and families, all of which have a bearing on interventions locally
 1722 and globally. In addition, global issues of stigma, governance and paucity of resources also have to be
 1723 taken into account²⁸⁵.

1724

1725

Box 3. Top ten questions for autism research proposed by autistic people, family members and professionals^a.

1. Which interventions improve mental health or reduce mental health problems in people with autism? How should mental health interventions be adapted for the needs of people with autism?
2. Which interventions are effective in the development of communication and language skills in autism?
3. What are the most effective ways to support or provide social care for autistic adults?
4. Which interventions reduce anxiety in autistic people?
5. Which environment supports are most appropriate in terms of achieving the best education, life and social skills outcomes in autistic people?
6. How can parents and family members be supported and/or educated to care for and better understand an autistic relative?
7. How can autism diagnostic criteria be made more relevant for the adult population? And how do we ensure that autistic adults are appropriately assessed and diagnosed?
8. How can we encourage employers to apply person centred interventions and support to help autistic people maximize their potential and performance in the workplace?
9. How can sensory processing in autism be better understood?
10. How should service delivery for autistic people be improved and adapted in order to meet their needs?

^aBased on Ref ²³⁹

Box 4. Examples of autism websites

[H1] Sites for health care professionals or research scientists

- American Academy of Pediatrics: <https://www.aap.org/en-us/advocacy-and-policy/aap-health-initiatives/Pages/autism-initiatives.aspx>
- International Society for Autism Research: <https://www.autism-insar.org>
- National Autistic Society: <https://www.autism.org.uk>
- Royal College of General Practitioners: <https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/asd-toolkit.aspx>

[H1] Information about treatment, research and advocacy for people with autism and their families:

- Autism Canada: <https://autismcanada.org>
- Research Autism: <http://www.researchautism.net/>
- Autism Europe: <https://www.autismeurope.org/>
- Autism India: <http://www.autism-india.org>
- WHO: <https://www.who.int/news-room/fact-sheets/detail/autism-spectrum-disorders>
- Autism Spain: <http://www.autismo.org.es>
- Autism Speaks: www.autismspeaks.org
- Autismus Deutschland : <https://www.autismus.de>
- Autistica: <https://www.autistica.org.uk>

[H1] Information about research funding, and up-to-date information for people with autism and families

- Simons Foundation: <https://www.sfari.org>
- US NIH: <https://www.nimh.nih.gov/health/topics/autism-spectrum-disorders-asd/index.shtml>
- Autism Science Foundation : <https://autismsciencefoundation.org>

[H1] Epidemiological and surveillance information

- US CDC: <https://www.cdc.gov/ncbddd/autism/index.html>
- Adult population autism surveys, England: <https://digital.nhs.uk/data-and-information/publications/statistical/adult-psychiatric-morbidity-survey/adult-psychiatric-morbidity-survey-survey-of-mental-health-and-wellbeing-england-2014>
- Mental Health of Children and Young People (including autism) in England, 2017: <https://digital.nhs.uk/data-and-information/publications/statistical/mental-health-of-children-and-young-people-in-england/2017/2017>
- The University of Queensland Queensland Centre for Mental Health Research: Global Burden of Disease programme (autism): <https://www.uq.edu.au/news/article/2014/08/autism-rates-steady-two-decades>

ToC blurb

1791 Autism spectrum disorder - or autism - is a neurodevelopmental disorder that typically manifests in
1792 young children. This Primer by Lord and colleagues reviews the epidemiology, mechanisms, clinical
1793 detection and treatment of autism.